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ABSTRACT 
Bioengineering the Expression of Active Recombinant Human Cathepsin G, Enteropeptidase, 
Neutrophil Elastase, and C-Reactive Protein in Yeast 
 by 
Eliot T. Smith  
The yeasts Pichia pastoris and Kluyveromyces lactis were used to express several recombinant 
human proteins for further biochemical characterization.  Two substitution variants of 
recombinant human enteropeptidase light chain (rhEPL) were engineered to modify the extended 
substrate specificity of this serine protease.  Both were secreted as active enzymes in excess of 
1.7 mg/L in P. pastoris fermentation broth.  The substitution variant rhEPL R96Q showed 
significantly reduced specificities for the preferred substrate sequences DDDDK and DDDDR; 
however, the rhEPL Y174R variant displayed improved specificities for these substrate 
sequences relative to all other reported variants of this enzyme.  The neutrophil serine proteases 
human cathepsin G (hCatG) and human neutrophil elastase (HNE) were expressed in P. pastoris 
and HNE was also expressed in K. lactis.  The recombinant variants rhCatG and rHNE, with 
intact C-terminal extensions, were expressed as fusion proteins with the soluble heme-binding 
domain of cytochrome B5 (CytB5) and an N-terminal hexahistidine (6xHis) tag for purification.  
The CytB5 domain was linked to the native N-termini of active rhCatG and rHNE by the EPL-
cleavable substrate sequence DDDDK~I, where ~ is the sessile bond.  These fusion proteins 
were directed for secretion.  The yeast P. pastoris expressed up to 3.5 mg/L of EPL-activable 
rHNE in fermentation broth; however, only 200 µg/L of rhCatG could be produced by this 
method.  Recombinant expression in K. lactis never surpassed 100 µg/L of activable rHNE.  The 
CytB5 fusion domain was present in the heme-bound form, conferring a red color and 410 nm 
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absorbance peak to solutions containing the fusion proteins.  This absorbance pattern was most 
readily visible during the purification of CytB5-rHNE from P. pastoris.  Human C-reactive 
protein (hCRP) and the substitution variant CRP E42Q were expressed in recombinant form and 
secreted by P. pastoris.  Both products were found to bind phosphocholine (PCh) in the same 
manner as native hCRP.  Difficulties encountered during purification revealed that wild type 
recombinant CRP (rCRP) was produced at 2 different molecular masses.  The P. pastoris 
recombinant expression system yielded better results than K. lactis.  Bioreactor-scale 
fermentation in a 5 L vessel facilitated expression and characterization of these recombinant 
proteins.  
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CHAPTER 1 
INTRODUCTION 
 
Recombinant Protein Engineering 
Recombinant protein expression has emerged as a powerful tool for the biomedical 
sciences during the past several decades.  Researchers began using recombinant DNA 
technologies to reprogram Escherichia coli for protein expression in the 1970s (Marians et al. 
1976; Wood and Lee 1976; Itakura et al. 1977; Meagher et al. 1977; Miller et al. 1977a; Miller et 
al. 1977b).  Recombinant human insulin produced in E. coli was first approved by the FDA for 
therapeutic use in 1983 (Johnson 1983) and has since supplanted native porcine and bovine 
insulin as the preferred source of the drug.  In the decades since this innovation, the 
pharmaceutical industry has heavily pursued recombinant proteins as novel approaches to the 
treatment of many diseases.   
Recombinant protein expression technologies now enable a plethora of otherwise 
impossible experimental approaches.  Recombinant human proteins are often produced in large 
quantities for further experimentation.  Amino acid sequences are modified to study the 
contributions of individual residues to protein structures and functions.  Multiple protein 
domains with distinct properties can be coupled into fusion constructs that exhibit combined 
traits of the individual component proteins, a strategy that can be used to facilitate detection and 
purification.  Novel proteins can even be invented de novo, a promising science that is still in its 
infancy (Koga et al. 2012).  These pursuits, among many others that have evolved out of 
recombinant protein expression technologies, continue to provide new methods for biomedical 
research and yield novel medical treatments. 
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The general approach to recombinant protein expression begins with the molecular 
cloning of protein-coding DNA into a genetic vector and delivery of this programing into a 
suitable host organism (Marians et al. 1976; Wood and Lee 1976; Itakura et al. 1977; Meagher et 
al. 1977; Miller et al. 1977a; Miller et al. 1977b).  The transformed host can then express the 
encoded protein; however, the specific nature of any recombinant expression depends on the 
interplay of several factors including the traits of the chosen host organism, the nature of the 
genetic program, and the properties of the recombinant protein.   
 
Recombinant Expression Systems 
Many organisms are useful as hosts for recombinant protein expression, including 
especially bacterial, animal, and yeast cell types.  With distinct biological properties, each of 
these expression systems behaves differently and each is best suited to different project goals.  
Successful expression requires consideration of many factors in selecting an appropriate host 
organism as an expression platform. 
 Bacterial Systems.  E. coli strains are the most commonly used host organisms because 
they are prokaryotes and possess a simple genetic system.  The native genetics of these bacteria 
have been well-characterized and the genome sequences of many E. coli strains are available 
through the National Center for Biotechnology Information (NCBI) database.  Recombinant 
DNA is typically introduced using plasmid vectors that are easily manipulated with standard 
molecular cloning techniques.  E. coli can be transformed by electroporation or chemical means 
and transformants are routinely screened by overnight growth with antibiotic resistance selection 
on lysogeny broth (LB) agar plates.  Liquid cultures of E. coli grow quickly, can grow to high 
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cell densities, and generate large quantities of protein under proper conditions, thus these 
cultures are suitable for batch fermentation on an industrial scale. 
 E. coli do not contain the machinery required for eukaryotic post-translational processing 
steps like chaperone-aided folding, disulfide bond formation, glycosylation, and trafficking; 
consequently, large and complex proteins often express poorly in E. coli, commonly forming 
inclusion bodies within the cytosol.  These aggregates of insoluble, misfolded protein must be 
isolated from the lysed cells, solubilized, and refolded.  Such complicated processing can be 
difficult and time consuming, can require harsh chemical treatments and can significantly reduce 
the amount of functional protein that is recovered.  Despite these drawbacks, E. coli strains 
remain the first choice for many recombinant protein engineers due to organism simplicity, ease 
of manipulation, rapid growth, and industrial scalability. 
 Animal Systems.  In contrast to the simplicity of E. coli, animal cell lines, which are 
equipped with eukaryotic machinery, provide co- and post-translational processing that may be 
necessary for successful expression of many human proteins.  The variety of available 
mammalian cell types offers more options for customizing the expression system to the specific 
requirements of the target protein and the project.  This can be necessary for studies that require 
proteins to be produced in their native environs, such as experiments on trafficking, multienzyme 
pathways, and membrane-associated proteins. 
 Despite these advantages, expression systems based on animal cell lines suffer from 
many drawbacks.  Stable, permanent genetic manipulations do not occur as readily in animal 
cells as they do in many microorganisms, making transformants more difficult to generate.  
Many animal cell lines do not grow in suspension and require an adherent surface; furthermore, 
such cell lines grow slowly and are poorly suited for industrial scalability.  Even cell lines that do 
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grow in suspension and scale well for industrial purposes typically need complex growth media, 
often containing fetal bovine serum (FBS) and other specialized components that 
microorganisms do not require.  Total protein yields are often low because of the complexity of 
animal host cells.  Ultimately, the use of animal cells incurs higher costs, requires more time, and 
may still result in low yield protein expression. 
 Yeast Systems.  Yeast species such as Saccharomyces cerevisiae, Pichia pastoris, and 
Kluyveromyces lactis provide many of the advantages of both bacterial and animal expression 
systems while eliminating many drawbacks because they are single-cell fungi.  Yeast genetics 
are well-characterized and easily manipulated.  E. coli retain their recombinant genetic 
programming as plasmids that can be lost with time and lack of selection pressure and stable 
transformants of animal cells can be difficult to generate and screen.  Many expression systems 
for yeast, however, rely on homologous recombination to insert the new genes directly into the 
host genome.  This yields many stable transformants that grow rapidly and are easy to screen, 
with almost no risk of the cells losing their programing over time.  Yeasts grow rapidly in 
suspension to high cell densities and require simple media formulations and environmental 
conditions.  They are also very well suited to large batch fermentations; furthermore, they often 
yield milligrams or grams of protein per liter of fermentation broth, making them useful for 
industrial scale production. 
 Yeasts contain machinery for co- and post-translational modifications that are often 
required for proper expression of human proteins; furthermore, lack of inclusion body formation, 
a problem with E. coli, results in high yield recovery of properly folded proteins without the need 
for harsh resolubilizing and refolding procedures.  Although some yeast strains are known to 
hyperglycosylate recombinant proteins (Niles et al. 1998; van Oort et al. 2002; van Oort et al. 
21 
 
2004; Lockhart et al. 2005; Pepeliaev et al. 2011), more recently engineered strains of P. pastoris 
can express proteins with several specific types of mammalian glycosylation (Pichia 
GlycoSwitch®; http://www.rctech.com/licensing/gxt-pichia-glycoswitch.php).  Through the use 
of yeast secretion signals like α-mating factor, recombinant proteins can be directed for secretion 
into the growth media; consequently, this can eliminate the need for cell lysis. 
 
P. pastoris and K. lactis as Recombinant Expression Systems 
 Recombinant expression systems based on the yeast species P. pastoris and K. lactis have 
become well established and new improvements continue to emerge.  Many expression plasmids 
have been developed that apply various strategies to enable successful expression in both 
species.  Genetic programs available in these plasmids include options for inducible or 
constitutive promoters, amino- (N-) and carboxyl (C-) terminal fusion tags, multiple reading 
frames, and secreted or internal expression.  Existing plasmids can, furthermore, be modified 
through standard molecular cloning procedures to completely customize any aspect of the vector.  
Homologous recombination is generally exploited to insert copies of linearized plasmid DNA, 
called insertion cassettes, into the host genome.  This creates a permanent stable transformation 
of the cells into a new strain that expresses the recombinant protein construct of interest. 
 P. pastoris Expression System.  Plasmids frequently used for expression in the 
methylotrophic yeast P. pastoris include variants of the pPIC family (Life Technologies) that use 
the yeast’s methanol-inducible AOX1 gene transcriptional promoter.  This promoter provides 
tight regulation of recombinant protein expression based on the choice of carbon source because 
it is repressed by glucose and glycerol and induced by methanol, which the yeast can metabolize 
as the sole carbon source; furthermore, such strong control of induction can benefit the 
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expression of toxic proteins.  Clones containing multiple repeat tandem copies of the insertion 
cassette occur with high frequency and can improve protein expression levels.   
The pPICzα plasmids encode the secretion signal propeptide sequence for yeast α-mating 
factor that directs recombinant proteins for secretion into the growth medium, whereas pPICz 
plasmids lack this sequence and result in intracellular protein accumulation.  The α-mating factor 
propeptide is removed from the N-terminus during secretion by including the sequence of a 
cleavage target site for the furin-like protease kexin, resulting in production of recombinant 
protein with a native N-terminus that is present in the culture supernatant.   
The pPICz and pPICzα plasmids contain a gene for resistance to the antibiotic Zeocin 
(Life Technologies) that enables selection of transformed P. pastoris and E. coli.  Zeocin 
selection produces virtually no background of untransformed clones and serves to prevent later 
contamination of transformant stocks with untransformed cells.   
 K. lactis Expression System.  The plasmid pKLAC1 (New England Biolabs) is designed 
for homologous recombination of multiple repeat tandem copies of the cassette into the genome 
of K. lactis under control of the galactose-inducible LAC4 promoter, also repressed by glucose 
and glycerol.  Galactose has the advantage of being nonflammable, unlike the methanol used for 
induction of AOX1.  As with pPICzα, pKLAC1 encodes the yeast α-mating factor signal 
propeptide sequence that is removed by kexin in the Golgi apparatus and results in secretion of 
mature proteins with native N-termini.   
To isolate transformants, pKLAC1 uses ampicillin antibiotic resistance selection for E. 
coli and acetamide metabolism selection for K. lactis (Read et al. 2007).  The plasmid transforms 
K. lactis to express the enzyme acetamidase that is required for the metabolism of acetamide as a 
nitrogen source; consequently, plating on nitrogen-free, yeast carbon base (YCB) agar containing 
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acetamide selects for growth of transformed clones.  This selection process improves the 
selection of multicopy transformants; however, it can generate a background of colonies that 
slowly metabolize acetamide and can be difficult to distinguish from true transformants. 
 
Custom Tailored Gene Synthesis and Codon Usage Optimization 
Traditional methods for cloning typically use reverse transcription polymerase chain 
reaction (RT-PCR) to create and amplify complementary DNA (cDNA) copies of a naturally 
occurring, intron-free, mRNA that encodes the protein of interest.  PCR primers can be designed 
to incorporate suitable restriction endonuclease cleavage sites that then facilitate cloning into a 
chosen vector.  In contrast to this approach, custom gene synthesis has many advantages that 
simplify the cloning process, enhance the malleability of the gene and protein sequences, and 
improve expression levels of recombinant proteins.   Commercially synthesized genes of any 
nucleotide sequence can be customized with any features such as restriction endonuclease 
recognition sequences for molecular cloning into vectors; similarly, undesirable restriction 
endonuclease sites and mRNA secondary structure can be eliminated from the sequence through 
the use of alternative codons.  Custom synthesis facilitates the engineering of multiple-domain 
fusion proteins, especially those whose component sequences deviate significantly from their 
naturally occurring mRNA counterparts.   
Because not all species express the same levels of the same tRNAs, different organisms 
translate individual codons with varying efficiencies.  This phenomenon of codon usage 
preference can have considerable impact on protein production in foreign hosts because the 
codons most prevalent in the recombinant gene may not correspond to the codons used most 
efficiently by the expression system.  This can cause ribosomal stalling and disassembly that 
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result in incomplete, partially translated proteins and a reduction in the efficiency of protein 
production. 
DNA sequence databases have been analyzed extensively to determine the statistical 
frequencies with which codons occur within the total population of characterized protein-coding 
genes for many species (Nakamura et al. 2000).  These data are available publicly 
(http://www.kazusa.or.jp/codon/) (Nakamura et al. 2000) and an internet website 
(http://gcua.schoedl.de/index.html) (Fuhrmann et al. 2004) facilitates comparisons of codon 
usage for gene sequences between organisms. 
A comparison of the codon usage tables for the relative frequencies (RFs) of several 
amino acids in Homo sapiens, P. pastoris, and K. lactis reveals some important differences 
(Figure 1.1).  For example, among the 6 available codons for the amino acid Arg, the codons 
AGA, AGG, CGC, and CGG each appear approximately 20% of the time in human genes 
(Figure 1.1a); however, the codon AGA is used in 48% and 51% of total Arg codon occurrences 
in P. pastoris and K. lactis, respectively, (Figure 1.1b).  Also, the sequences CGC and CGG each 
only occur as 5% of the Arg codons in P. pastoris and K. lactis although they appear more 
frequently in human genes.  Gln provides another good example in that the codon CAG is 
preferred, with RF = 73%, in human genes, whereas CAA is the preferred codon, with RF = 61% 
and 67% in P. pastoris and K. lactis, respectively.  Frequency of codon occurrence may correlate 
with protein translation efficiency; however, data are lacking that directly characterize the 
relative frequencies of tRNA expression in different organisms.   
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Figure 1.1:  Codon Usage Frequency.  Partial comparison shows differences in relative codon 
usage frequencies between H. sapiens (blue), P. pastoris (black), and K. lactis (red).  Data 
represent the relative frequency (RF) as a percentage of total codon occurrences for the given 
amino acid in the genome of the species indicated.  A. H. sapiens and P. pastoris.  B. K. lactis 
and P. pastoris.  Images adapted from http://gcua.schoedl.de/index.html. 
 
Custom DNA synthesis facilitates the optimization of codon usage within a recombinant 
gene to match the codon preferences of the protein expression system (Figure 1.2).  For example, 
Figure 1.2 shows a codon optimization of the first 50 residues of active human neutrophil 
elastase (HNE) for P. pastoris codon usage frequency tables.  Figure 1.2a shows the native 
human cDNA sequence, by codon, along with the relative adaptiveness (RA) of that codon for 
expression in P. pastoris.  Unlike the RF (Figure 1.1), the RA designates a value of 100% for the 
most frequently used codon for a given amino acid and the RA values for the other analogous 
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codons are presented as a percentage of the most frequently used codon.  The RA measurement 
scale is preferred over RF for comparing cDNA sequences because it facilitates rapid visual 
interpretation of the data. 
 
 
Figure 1.2:  Codon Optimization.  Codon usage analysis is shown for expression in P. pastoris 
based on relative adaptiveness (RA).  The codons are shown for the amino acids Ile16-Ala66 of 
(A) Native HNE cDNA and (B) Recombinant HNE cDNA that is codon optimized for P. 
pastoris.  RA represents the percentage of codon usage relative to the codon most frequently 
used for the given amino acid by P. pastoris.  Codons of low occurrence with RA >15% appear 
in gray and those with RA >10% appear in red (A).  Codon optimization replaces these codons 
with sequences more prevalent in the target genome (B).  Images adapted from 
http://gcua.schoedl.de/index.html. 
  
Figure 1.2a shows that the codons used in the native human cDNA are not the codons 
most preferred by P. pastoris, especially in the cases of 4 Arg residues with RA = 10% and six 
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Ala residues with RA = 13%.  A synthetic cDNA for the same amino acid sequence codon-
optimized for expression in P. pastoris (Figure 1.2b) incorporates codons with much higher RF 
in the yeast that results in higher RA values in the cDNA.  The most preferred codon is not 
always chosen, however, in order to avoid mRNA self-complementarity that forms stable 
secondary structures, intron splicing sites, and unwanted internal restriction sites.  This process 
of codon optimization can have robust positive effects on expression levels, although such 
effects are not always experienced.  
 
Designing Recombinant Proteins 
 Recombinant protein expression technologies facilitate endeavors in protein 
experimentation and design.  Amino acid substitutions by site directed mutagenesis are useful for 
studying the contributions of individual residues to the overall structural and functional 
characteristics of a given protein.  Fusion proteins can be created by linking multiple distinct 
protein domains to combine their individual properties into a single molecular chimera, a process 
whose benefits are limited only by the folding and functionality of the selected domains.  Amino 
acid sequences with known molecular recognition and binding properties can be exploited to 
affect the functionality of the product. 
 Amino Acid Substitutions and Deletions.  Custom gene synthesis and site-directed 
mutagenesis can be used to selectively replace individual amino acid residues within a 
recombinant protein.  Such substitutions prove advantageous in recombinant protein expression 
for many reasons.  Residues with key roles in enzyme specificity, activity, and other functions 
can be manipulated individually to determine the effects of their replacement and alter the 
behaviors of proteins.  Similarly, entire regions of native proteins can be deleted to evaluate their 
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contributions to processes such as protein trafficking, DNA and RNA binding, signaling, and 
enzymatic activity.  Although alterations of amino acid sequence can have unintended 
consequences, even these results can provide insights into the roles of individual residues in 
protein behavior. 
 It has been shown that many proteins of high isoelectric point (pI) do not express well in 
the yeast P. pastoris (Boettner et al. 2007).  Often, highly charged proteins are susceptible to 
proteolysis due to the high content of arginine and lysine residues, which can be substrates for 
many proteases.  Of particular concern for secreted expression in yeast, a high frequency of basic 
residues increases the likelihood that the dibasic sequences RR~X and KR~X, substrates for the 
yeast protease kexin, will occur that may lead to unwanted proteolysis during protein secretion.  
These issues can be ameliorated by the selective substitution of amino acids to eliminate such 
sites. 
 Known and potential sites of co- and post-translational modification can also be 
manipulated or disrupted to evaluate their roles in normal biological processes.  This can aid in 
the evaluation of potential sites of glycosylation, phosphorylation, proteolysis, or other 
modifications to determine how these processes affect the behavior of a protein.  As previously 
mentioned, many yeast species are prone to over glycosylate recombinant proteins (Niles et al. 
1998 ; van Oort et al. 2002; van Oort et al. 2004; Lockhart et al. 2005; Pepeliaev et al. 2011); 
furthermore, many biochemical studies require the enzymatic removal of glycosylation.  
Conservative amino acid substitution to eliminate glycosylation sites can prevent these issues 
and simplify research efforts. 
 Fusion Proteins and Tags.  By combining sequences for different protein domains into a 
single polypeptide chain, a fusion protein can be expressed that exhibits the properties of its 
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individual, modular components.  Several types of domains are frequently exploited to improve 
the expression, detection, and purification of recombinant proteins.  With some creativity, novel 
approaches can also be engineered that take advantage of protein properties in other ways 
through their inclusion in a fusion design. 
 As mentioned above, the yeast α-mating factor signal sequence is often exploited to 
direct recombinant proteins for secretion by both P. pastoris and K. lactis and this can be used to 
improve expression and recovery of recombinant proteins.  Secreted proteins do not require cell 
lysis prior to purification, nor are they as prone to rapid degradation as proteins expressed inside 
the cell, although some extracellular proteases are produced.  In E. coli, recombinant proteins 
commonly accumulate as insoluble inclusion bodies that require harsh chemical treatments to 
solubilize and refold, often resulting in poor yields; consequently, highly soluble proteins such as 
thioredoxin, serum albumin, or small ubiquitin-like modifier (SUMO) protein are sometimes 
tethered to desired recombinants in efforts to thwart inclusion body formation, thus improving 
expression and recovery. 
 Numerous fusion domains are available to facilitate detection of recombinant proteins as 
well.  Several fluorogenic proteins based on the Aequorea victoria green fluorescent protein 
(GFP) (Prasher et al. 1992; Chalfie et al. 1994; Inouye and Tsuji 1994) have been engineered that 
exhibit fluorescent properties across a spectrum of colors including cyan (Heim and Tsien 1996; 
Tsien 1998), blue (Heim et al. 1994; Heim and Tsien 1996), green (Yang et al. 1996; Tsien 1998; 
Zapata-Hommer and Griesbeck 2003), and yellow (Ormö et al. 1996; Wachter et al. 1998).  
Fluorescent proteins based on the red fluorescent protein of Discosoma species have also been 
developed in a range of fluorescent colors spanning cyan to far-red (Matz et al. 1999; Campbell 
et al. 2002; Shaner et al. 2004; Wang et al. 2004; Shaner et al. 2005; Shu et al. 2006; Shaner et 
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al. 2007; Alieva et al. 2008; Shaner et al. 2008; Shaner 2013).  Protein fluorescence is often used 
to visualize protein localization and transport by fluorescence microscopy; furthermore, studies 
of transcriptional promoters as well as protein-DNA and protein-protein interactions can be 
facilitated through the use of fluorescent proteins as reporter genes for experiments in promoter 
alteration or yeast two-hybridization. 
Limited work has also been done regarding the use of chromogenic proteins as fusion 
partners, although few such proteins are known.  Rubredoxin, which binds iron, and the heme-
binding protein cytochrome B5 (CytB5) both display a characteristic absorbance of light at 410 
nm accompanied by a red coloration and have been used to detect the expression of their 
recombinant fusions (Kohli and Ostermeier 2003; Finn et al. 2005; Mitra et al. 2005).  With a 
higher extinction coefficient at 410 nm, CytB5 provides a stronger, more easily detectable signal 
than rubredoxin (Mitra et al. 2005).  The flavin mononucleotide (FMN)-binding domain of 
human cytochrome P450 reductase has also been used for its characteristic yellow color and 
absorbance at 450 nm (Finn et al. 2005).  While the detection of fluorescent proteins requires 
specialized equipment, chromogenic proteins can be detected visually and by simple 
spectrophotometry and this makes them useful for following recombinant protein expression and 
purification. 
Antibody epitope short peptide tags like the myc-tag (EQKLISEEDL), the FLAG® tag 
(DYKDDDDK) (Sigma), and polyhistidine tags that can be added to the N- or C- terminus of a 
protein see considerable use for detection and they can also be useful for purification.  
Antibodies are available that recognize each of these sequences and this is especially useful for 
Western blotting, ELISA, immunohistochemistry (IHC), and immunocytochemistry (ICC).  
Myc-tag and FLAG® tag monoclonal antibodies can also be used to purify proteins by antibody 
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affinity chromatography.  Polyhistidine tags, most commonly the hexahistidine (6xHis) tag, will 
bind divalent metal cations like Co
2+
, Cu
2+
, and Ni
2+
 by sharing electrons and this can be 
exploited to purify polyhistidine tagged proteins by immobilized metal affinity chromatography 
(IMAC) (Hochuli 1988). 
Designing Internal Proteolytic Sites.  Because many recombinant fusion proteins require 
the separation of fusion partners by proteolysis for proper function or further study, proteolytic 
sites can be incorporated; however, few proteases possess the high level of substrate specificity 
required to prevent unintended proteolytic events.  Among the most commonly used proteases 
for this purpose are coagulation factor Xa, thrombin, tobacco etch virus (TEV) protease, and 
enteropeptidase.  The commonly used thrombin cleavage site is LVPR~GS and the usual TEV 
protease cleavage sites are ENLYFQ~G and ENLYFQ~S (where “~” represents the cleavage 
site); however, these approaches leave G or S (TEV protease) or GS (thrombin) at the N-
terminus of the C-terminal domain, which can be problematic, especially for the activation of 
enzymes, such as serine proteases, whose functions require an exposed native N-terminus.   
Factor Xa, which turns prothrombin into active thrombin and prefers the sequences 
IEGR~X and IDGR~X (where X can be any amino acid other than proline), and enteropeptidase 
(EP, originally called enterokinase), which converts inactive trypsinogen into active trypsin and 
prefers the sequences DDDDK~X (LaVallie et al. 1993; Lu et al. 1997) and DDDDR~X 
substrates (Mikhailova et al. 2007; Gasparian et al. 2011; Smith and Johnson 2013), have been 
nicknamed “restriction proteases” for their extreme substrate specificities, similar to the well-
known restriction endonucleases from which the moniker is derived.  Unlike thrombin and TEV 
protease, factor Xa and EP exhibit no preference for amino acids on the P’ side (nomenclature of 
Schechter and Berger (Schechter and Berger 1967)) of the target peptide bond; consequently, the 
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specificities of these 2 enzymes can be used to expose the native N-termini of proteins upon the 
removal of fusion domains. 
Although EP has high preference for the DDDDK~X (LaVallie et al. 1993; Lu et al. 
1997) and DDDDR~X (Mikhailova et al. 2007; Gasparian et al. 2011) substrate sequences, this 
protease will cleave other sequences with significantly lower specificity in the absence of a 
sufficient concentration of the intended target enzyme (Light et al. 1980; Likhareva et al. 2002; 
Liew et al. 2005; Shahravan et al. 2008; Chen et al. 2012).  The enzyme’s preference comes from 
charge-based attractions to the substrate.  The positively charged Lys (K) or Arg (R) in the P1 
position is drawn into the negatively charged S1 specificity pocket of EP; furthermore, the 4 
negatively charged Asp (D) residues coordinate with positively charged, adjacent residues on the 
enzyme surface.  While EP from all species use a negatively charged Asp 189 
(chymotrypsinogen numbering system) at the base of the S1 pocket, species-specific differences 
in positive charge distribution in the S2 – S4 sites affect the extended substrate specificity.  It is 
possible to use recombinant protein engineering to create modified variants of EP that 
manipulate this positive charge distribution to alter or improve the enzyme’s substrate specificity 
(Chun et al. 2011; Ostapchenko et al. 2012; Smith and Johnson 2013). 
Chapter 2 presents the recombinant expression of 2 variants of the light chain of human 
EP with modified substrate specificities.  Both variants were secreted by P. pastoris as functional 
enzymes and purified to homogeneity.  One variant, R96Q, reduced the specificity of EP for the 
extended substrates DDDDK~X and DDDDR~X by reducing the amount of positive charge in 
the extended binding pocket.  The other EP substitution variant, Y174R, improved the enzyme’s 
specificity significantly for both substrates through the addition of positive charge to improve 
charge based interactions between the substrates and the extended binding site.  
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Serine Proteases 
 Enteropeptidase, factor Xa, and thrombin are members of the chymotrypsin-like S1 clan 
of serine proteases, characterized by the high similarity of their tertiary structures and by their 
identical active site architecture.  All serine proteases are related through the use of an electron 
relay mechanism that activates a nucleophilic oxygen atom on the side chain of the eponymous 
serine residue in the active site.  Among the chymotrypsin-like serine proteases, the active site 
consists of 3 residues: His 57, Asp 102, and Ser 195 (chymotrypsinogen numbering system) 
(Ressler 1985; Craik et al. 1987; Sprang et al. 1987; Carter and Wells 1988; Polgár 2005; 
Fuhrmann et al. 2006) that are arranged so that His 57, stabilized by Asp 102, withdraws the H
+
 
atom from the side chain oxygen of Ser 195.  The topology and charge distribution of the 
substrate binding grooves of serine proteases position selected protein substrates so that the 
activated serine nucleophile attacks the carbonyl carbon of a target peptide bond to form a 
tetrahedral intermediate that then undergoes hydrolysis as the enzyme catalyst releases the 
resulting product fragments and returns to its original nucleophile form. 
 The roles of serine proteases in numerous biological processes and diseases emphasize 
their importance in biomedical research.  Blood coagulation is initiated by an activation cascade 
of either 3 (extrinsic pathway) or 6 (intrinsic pathway) serine proteases, resulting in the 
generation of active thrombin that converts inert fibrinogen into clot-forming fibrin (Davie and 
Ratnoff 1964; MacFarlane 1964); furthermore, disruptions in this protease activation cascade 
cause hemophilia.  In the duodenum (Hermon-Taylor et al. 1977), enteropeptidase converts 
trypsinogen into active trypsin, a serine protease with broad specificity for positively charged P1 
residues (Schechter-Berger nomenclature) (Schechter and Berger 1967).  This initiates a cascade 
of digestive enzyme activation including the three archetypal S1 clan serine proteases: trypsin, 
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chymotrypsin, and pancreatic elastase.  These 3 proteases digest proteins into single amino acids 
and dipeptides for intestinal absorption.  Deficiencies in enteropeptidase (Haworth et al. 1971; 
Hadorn et al. 1975) and trypsin (Townes 1965) lead to digestive disorders with symptoms 
including intestinal malabsorption, hypoproteinemia, and growth failure.  These are only 2 
examples of the innumerable functions of serine proteases in human physiology and disease.    
 
Neutrophil Serine Proteases of Primary (Azurophil) Granules 
 Neutrophils are the most abundant type of white blood cell and the human body’s first 
line of defense against invasion by pathogenic bacteria and fungi (Borregaard and Cowland 
1997; Borregaard et al. 2005).  Also known as polymorphonuclear (PMN) leukocytes, 
neutrophils engulf and destroy infiltrators by phagocytosis, at which time primary (azurophil) 
granules fuse with the phagolysosome and release their cytotoxic contents upon the pathogen.  
The primary granules of neutrophils store large amounts of the enzyme myeloperoxidase (MPO) 
and the chymotrypsin-like neutrophil serine proteases (NSPs) cathepsin G (CatG), human 
neutrophil elastase (HNE), and proteinase 3 (Pr3, also called myeloblastin), in addition to several 
other antimicrobial proteins (Faurschou and Borregaard 2003; Garwicz et al. 2005; Pham 2006).   
While the oxidative stress of MPO-derived hypochlorous acid was originally considered 
the primary means of microbial killing, research has since shown that NSPs of the azurophil 
granules play important, nonredundant roles in neutrophil lethality (Belaaouaj et al. 1998; 
Belaaouaj et al. 2000; Tkalcevic et al. 2000; Belaaouaj 2002; Reeves et al. 2002; Hirche et al. 
2004; López-Boado et al. 2004; Urban et al. 2006); furthermore, the killing functions of these 
NSPs are not limited to their proteolytic activity, but also a result of abundant positively charged 
residues.  Antimicrobial peptides of strong positive charge are released by the degradation of 
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NSPs and both the positively charged enzymes and peptides can associate with the negatively 
charged surfaces of microorganisms and exert cytotoxic effects independent of proteolytic 
activity (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 1991; Miyasaki et al. 1993; 
Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002; Korkmaz et al. 2010).  In a recently 
discovered extracellular killing mechanism, the neutrophil extracellular trap (NET), neutrophils 
also release a network of enzyme-laden chromatin to ensnare and destroy microbes in the 
extracellular milieu (Brinkmann et al. 2004; Urban et al. 2006; Wartha et al. 2007; 
Papayannopoulos et al. 2010; Amulic and Hayes 2011).  
 CatG, HNE, and Pr3 not only function to directly destroy pathogens but also to affect the 
inflammatory response through signaling pathways.  These enzymes process cytokines (Scuderi 
et al. 1991; Bank et al. 1999; Benabid et al. 2012), chemokines (Padrines et al. 1994; Nufer et al. 
1999; Rao et al. 2004; Berahovich et al. 2005; Ryu et al. 2005; Wittamer et al. 2005), and 
protease activated receptors (PARs) (Sambrano et al. 2000; Cumashi et al. 2001) with both 
proinflammatory and antiinflammatory consequences (Pham 2006; Korkmaz et al. 2008; 
Korkmaz et al. 2010).   Although Pr3 and CatG cleave chemokines that promote monocyte 
chemotaxis (Padrines et al. 1994; Nufer et al. 1999; Berahovich et al. 2005) and HNE and CatG 
action can cause recruitment of antigen-presenting macrophages and dendritic cells (Wittamer et 
al. 2005), the net effects of NSPs on inflammation and immune cell recruitment remain unclear 
because these enzymes also process several antiinflammatory chemokines and cytokines as well.  
For example, both CatG and HNE inactivate TNFα (Scuderi et al. 1991), whereas Pr3 activates 
this proinflammatory cytokine (Robache-Gallea et al. 1995); however, CatG, HNE, and Pr3 all 
inactivate the proinflammatory cytokine IL-6 (Bank et al. 1999).   
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 The NSPs of azurophil granules have also been implicated in several human diseases 
associated with inflammation and tissue destruction (Korkmaz et al. 2008; Korkmaz et al. 2010).  
These enzymes have strong proteolytic activities and are present in abundance at sites of 
inflammation; furthermore, they can destroy host tissues if improperly regulated.  They can all 
cleave collagens, elastin, fibronectin, laminin, and proteoglycans (Starkey 1977; Pipoly and 
Crouch 1987; Rao et al. 1991; Korkmaz et al. 2008), making them particularly damaging to 
extracellular matrices and connective tissues, especially in inflammatory lung diseases like acute 
lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disorder 
(COPD), cystic fibrosis, and emphysema (Lee and Downey 2001a; 2001b; Shapiro 2002; Moraes 
et al. 2003; Shapiro et al. 2003; Moraes et al. 2006; Korkmaz et al. 2008; Owen 2008; Korkmaz 
et al. 2010).   
 CatG, HNE, and Pr3 are all synthesized in the promyelocytic stage of early neutrophil 
maturation as inactive preproproteins and directed to the primary granules (Gullberg et al. 1997; 
Garwicz et al. 1998; Garwicz et al. 2005).  Although the key component of NSP sorting into 
these granules is the timing of their biosynthesis, the molecular means by which the enzymes are 
directed to their eventual destinations is unclear (Korkmaz et al. 2008; Korkmaz et al. 2010).  All 
3 inactive proteins contain N-terminal leader sequences that direct them into the rough 
endoplasmic reticulum and are removed during posttranslational processing (Salvesen and 
Enghild 1991; McGuire et al. 1993; Sköld et al. 2002; Korkmaz et al. 2008).  The resulting NSP 
zymogens contain N-terminal prodipeptides that are removed by dipeptidyl peptidase I (DPP I, 
also called Cathepsin C) inside the granules to expose the native N-terminal Ile 16, required for 
the activity of all chymotrypsin-like serine proteases (Salvesen and Enghild 1991; McGuire et al. 
1993; Sköld et al. 2002; Korkmaz et al. 2008). 
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In addition to this type of zymogen activation, which is common to all members of the S1 
clan, CatG, HNE, and Pr3 also contain unusual C-terminal propeptide extensions (“tails”) of 
varying lengths and sequences (Gullberg et al. 1995; Gullberg et al. 1997; Capizzi et al. 2003).  
In an evolutionarily conserved process, these C-terminal tails are removed by an unidentified 
protease (or proteases); furthermore, the tails are dissimilar and have no known functions.  They 
do not appear to affect the activities of the enzymes, nor are they required for correct 
intracellular trafficking (Gullberg et al. 1995; Källquist et al. 2010; Korkmaz et al. 2010).  An 
amino acid sequence alignment of CatG, HNE, and Pr3 (Figure 3.1) shows the relative positions 
of Ile 16, His 57, Asp 102, Ser 195, and the C-terminal extensions. 
 
 
Figure 1.3:  NSP Sequence Alignment.  Native sequences for human CatG, HNE, and Pr3 are 
aligned, illustrating similarities and differences.  All residues required for catalytic activity 
appear in green. The N-terminal Ile 16 ( ) must be exposed for catalytic activity.  The residues 
that comprise the catalytic triad ( ) include His 57, Asp 102, and Ser 195.  C-terminal 
propeptide extensions appear in bold with red underline. 
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 Human Proteinase 3.  Pr3 can be found not only in the primary granules and in NETs but 
also in secondary (specific) granules, secretory vesicles, and in association with the neutrophil 
cell surface (Korkmaz et al. 2008; Korkmaz et al. 2010).  This serine protease demonstrates a 
preference for short hydrophobic amino acid residues, especially Val, Ala, and Thr, in the P1 
position; furthermore, endogenous inhibitors of Pr3 include α2-macroglobulin, α1-antitrypsin 
(α1-AT, also called α1-proteinase inhibitor), and elafin (Korkmaz et al. 2008; Korkmaz et al. 
2010).  Mature Pr3 contains 222 amino acids (Campanelli et al. 1990), has an isoelectric point 
(pI) of ~9.5 and it bears a positive charge at physiologically relevant pH due to its high content 
of arginine (13 residues); consequently, Pr3 has bactericidal properties independent of its 
proteolytic function, as do HNE and CatG (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 
1991; Miyasaki et al. 1993; Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002; Korkmaz et 
al. 2010).  The C-terminal tail of Pr3, 8 amino acids in length, is the shortest among the azurophil 
granule NSPs and little is known about its function (Capizzi et al. 2003). 
 Antineutrophil cytoplasmic antibodies (ANCAs) are responsible for several diseases 
characterized by autoantibodies against neutrophils accompanied by blood vessel inflammation.  
Pr3 is the main antigen recognized by cytoplasmic ANCAs (cANCAs) and this phenomenon 
corresponds with the relatively uncommon disease Wegener’s Granulomatosis (WG), for which 
the cause is not fully understood (Campanelli et al. 1990; Rao et al. 1991; Specks et al. 1997; 
Capizzi et al. 2003; Caughey 2006; Korkmaz et al. 2010).   The primary symptoms of WG are 
vasculitis and necrotizing, granulomatous inflammation of small blood vessels (Fauci and Wolff 
1973; Sarraf and Sneller 2005); furthermore, it affects approximately 1 in 20,000 people, most 
between 40 – 60 years of age (Cotch et al. 1996).  Secondary symptoms can include cold or 
sinusitis that is not cured by normal means, inflammation of the ears or eyes, nasal membrane 
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crusting and ulceration, or saddle-nose deformity (Fauci and Wolff 1973; Sarraf and Sneller 
2005; Korkmaz et al. 2010).  According to the National Institute of Allergy and Infectious 
Disease, WG is typically treated with glucocorticoids and cytotoxic compounds 
(http://www.niaid.nih.gov/topics/wegeners/pages/treatment.aspx). 
Human Neutrophil Elastase.  HNE shares 54% sequence identity with Pr3; however, 
unlike Pr3, HNE is localized in NETs and the azurophil granules but not in other granules or 
vesicles, although some HNE is also associated with the neutrophil cell surface and in the 
nucleus (Pham 2006; Korkmaz et al. 2008; Korkmaz et al. 2010).  Similar to Pr3, HNE also 
prefers small hydrophobic residues at the P1 position, especially Val, Ile, Thr, Ala, and Leu 
(Bode et al. 1986).  Still, HNE and Pr3 do not share extended substrate specificity for residues in 
other positions; consequently, they process different proteins and play separate roles in 
neutrophil function.  Mature HNE contains 218 amino acids (Bode et al. 1986; Sinha et al. 1987) 
and has a pI of ~10.8, making it more positively charged than Pr3 under physiological 
conditions.  This strong positive charge results from 19 arginine residues and also gives HNE 
antibacterial properties independent of catalytic activity (Korkmaz et al. 2010).  HNE is inhibited 
physiologically by the same inhibitors as PR3: α2-macroglobulin, α1-AT, and elafin; however, 
HNE is also inhibited by secretory leukocyte proteinase inhibitor (SLPI), which does not inhibit 
Pr3 (Korkmaz et al. 2008; Korkmaz et al. 2010). 
The C-terminal tail of HNE is 20 amino acids long, the longest among the 3 azurophil 
granule NSPs; furthermore, it has been studied more extensively that the tails of Pr3 or CatG 
because of its potential role in severe congenital neutropenia (SCN), discussed below.  Although 
the C-terminal extension is not required for the granular localization of HNE, the presence of the 
tail does direct at least a portion of HNE to the cell membrane prior to reuptake of the enzyme by 
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endocytosis (Tapper et al. 2006); furthermore, blocking the tail of HNE with a fusion extension 
prevents this reuptake (Källquist et al. 2010).  Trafficking of Pr3 does not occur in the same 
manner (Källquist et al. 2010).  The removal of the C-terminal tail exposes a recognition site for 
the µ3a subunit of the adaptor protein 3 (AP3) complex (Benson et al. 2003).  It was previously 
suggested that the µ3a subunit may bind HNE at this site to direct granular localization (Benson 
et al. 2003); however, a more recent model suggests that the tetraspanin CD63 associates with 
HNE to mediate AP3-dependent trafficking (Källquist et al. 2008). 
Cyclic neutropenia (CN, also called cyclic hematopoiesis), and SCN are diseases of 
neutrophil maturation caused primarily by mutations in the HNE gene, ELANE (Horwitz et al. 
1999; Dale et al. 2000; Li and Horwitz 2001; Benson et al. 2003; Horwitz et al. 2004; Horwitz et 
al. 2007; Korkmaz et al. 2010; Horwitz et al. 2013).  CN is characterized by neutrophil counts 
that oscillate between normal and almost zero with a 21-day cycling time (Krance et al. 1982; 
Lange 1983).  In a genomic study of 13 families with a history CN, 7 heterozygous mutations of 
ELANE are found in all cases (Horwitz et al. 1999).  SCN is a disease of neutrophil maturation 
arrest, with symptoms including chronic low circulating neutrophil counts, structurally abnormal 
neutrophils with functional deficiencies, and increased susceptibility to infections (Kostmann 
1956; 1975; Carlsson and Fasth 2001; Horwitz et al. 2003; Horwitz et al. 2007;).  Although other 
gene mutations have been implicated in some, 21 out of 27 independent cases of SCN show 1 of 
15 different heterozygous mutations of ELANE (that sometimes also overlap with mutations that 
cause CN) (Dale et al. 2000).  All chain-terminating mutations of ELANE that result in 
production of C-terminally truncated HNE, which accompany many cases of SCN but not CN, 
occur in the fifth (final) exon (Benson et al. 2003; Horwitz et al. 2013). 
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Two hypotheses have been proposed for how HNE can cause CN and SCN.  The 
mislocalization hypothesis is based on canine cyclic neutropenia, or gray collie syndrome, in 
which mutations of the beta subunit of AP3 lead to mislocalization of HNE (Benson et al. 2003); 
however, the human disease most analogous to canine cyclic neutropenia is Hermansky-Pudlak 
syndrome and not CN or SCN (Horwitz et al. 2013).   The second hypothesis suggests that the 
offending ELANE mutations cause misfolding of HNE and induction of an unfolded protein 
response that leads to neutrophil apoptosis (Köllner et al. 2006).  Several neutropenia-causing 
mutations of ELANE lead to the cytoplasmic accumulation of unfolded HNE causing apoptosis 
in transformed U937 cells (Köllner et al. 2006). 
 Human Cathepsin G.  CatG appears only in the azurophil granules, on the neutrophil cell 
surface, and in NETs (Pham 2006; Korkmaz et al. 2008; Korkmaz et al. 2010).  The broad, 
hydrophobic S1 binding pocket of CatG confers a chymotrypsin-like P1 specificity for the 
hydrophobic aromatic amino acid residues Tyr and Phe; however, a positively charged Glu 226 
side chain resides at the base of the specificity pocket that also gives CatG trypsin-like P1 
specificity for the positively charged amino acids Lys and Arg (Tanaka et al. 1985; Hof et al. 
1996).  This dual specificity is unusual among serine proteases and warrants further biochemical 
research.  Mature CatG has an uncommonly high pI of ~12.0 because this protein, 224 amino 
acids in length (Salvesen et al. 1987; Hof et al. 1996), contains 34 Arg residues, 15.2 % of its 
total amino acid content.  Proteolytically inactive CatG and synthetic peptides derived from 
positively charged portions of the CatG amino acid sequence have strong antimicrobial 
properties (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 1991; Miyasaki et al. 1993; 
Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002).  CatG is endogenously inhibited by α2-
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macroglobulin, α1-AT, α1-antichymotrypsin, and SLPI, but not elafin, which inhibits HNE and 
Pr3 (Korkmaz et al. 2008; Korkmaz et al. 2010). 
 The C-terminal tail of CatG is 11 – 13 amino acids long and the exact site of its removal 
is unclear.  Among the available crystallographic models of mature native CatG, 3 show the 
presence of Ser 244 at the C-terminus (PDB ID: 1CGH, 1AU8, and 1T32) while 1 ends at Arg 
243 (PDB ID: 1KYN) (Hof et al. 1996; Greco et al. 2002; de Garavilla et al. 2005).  It is possible 
that CatG may remove its own tail by limited autolysis at Arg 243; however, CatG cannot 
remove the tail by cleaving at Ser 244, which appears to be the more common cleavage site.   
 Expression of Recombinant Human NSPs.  Recombinant human Pr3 has been expressed 
successfully in several animal cell lines including: U937 cells (Rao et al. 1996; Dublet et al. 
2005), Sf9 insect cells (Jenne and Kuhl 2006), RBL cells (Pederzoli et al. 2005), HMC-1 cells 
(Pederzoli et al. 2005; Jenne and Kuhl 2006), HEK239 cells (Jenne and Kuhl 2006), and COS 
cells (Källquist et al. 2010).  Much of this work has been spurred by the role of Pr3 as the key 
autoantigen in Wegener’s Granulomatosis (see above).  By contrast, HNE has been expressed 
only in COS cells (Okano et al. 1990; Källquist et al. 2008; Källquist et al. 2010) and in RBL-1 
cells (Gullberg et al. 1995; Tapper et al. 2006; Averhoff et al. 2008).  For CatG, the recombinant 
human enzyme has only been expressed in RBL cells or the murine myeloid cell line 32D 
(Gullberg et al. 1994; Garwicz et al. 1995; Gullberg et al. 1995), while mouse CatG (lacking 
trypsin-like substrate affinity found in primate and human CatG) and “humanized” mouse CatG 
(with the mutation A226E that bestows the trypsin-like substrate affinity) have been expressed in 
adherent Sf9 insect cells (Raymond et al. 2010). 
 While recombinant expression in mammalian cells has provided much information 
regarding azurophil granule NSPs, these systems do not produce large (milligram-to-gram) 
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quantities of protein efficiently, making them impractical for many in vitro biochemical studies.  
Active, full-length human Pr3, including the C-terminal tail with an added 6xHis tag for 
purification, was previously expressed in P. pastoris as a secreted protein with a yield of ~17 
mg/L (Harmsen et al. 1997); however, similar attempts with HNE only generated 100 µg/L of 
active enzyme and, separately, 1 mg/L of an enzymatically inactive H57A mutant, with low (5%) 
recovery yields (Dall'Acqua et al. 1999).  Cathepsin G has never been expressed as an active 
enzyme in any unicellular microorganism and the need persists for robust expression platforms 
for recombinant HNE and CatG. 
 Chapter 3 shows the successful expression and partial purification of recombinant HNE 
and human CatG, both with intact C-terminal tails, by secretion using P. pastoris and the AOX1 
methanol-inducible promoter.  Expression of HNE in K. lactis, with limited success, is also 
reported.  Both enzymes are produced as inactive protease zymogens with an N-terminal fusion 
domain connected by the EP cleavage site DDDDK~I; furthermore, these fusion proteins exhibit 
proteolytic activities after treatment with EP to expose their native Ile 16 N-termini.  The fusion 
partner linked to each of these enzymes is the soluble heme-binding domain of the red 
chromogenic protein cytochrome B5 (CytB5) with an N-terminal 6xHis tag for detection and 
purification.  Expression levels of active HNE in P. pastoris are improved 10 – 35 times 
compared to the previous attempts of others (Dall'Acqua et al. 1999), likely by producing an 
activable zymogen rather than the potentially toxic active enzyme.  Although less than 200 µg of 
active human CatG was expressed per liter of P. pastoris fermentation broth, this is the first 
reported successful recombinant expression of active human CatG using cells that grow in 
suspension in minimal growth medium to high culture density.  The results of this study suggest 
that the expression levels of HNE and human CatG in P. pastoris, as well as their purification, 
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can be improved with further efforts and that this yeast makes a suitable platform for the 
expression of useful quantities of modified NSPs. 
  
C-Reactive Protein 
 Human C-reactive protein (CRP) is a positive acute-phase reactant produced by 
hepatocytes and the circulating concentration of CRP  in the bloodstream increases significantly 
in response to upregulation of cytokine interleukin-6 (IL-6) as part of the nonspecific acute-
phase response (Pepys and Hirschfield 2003; Black et al. 2004).  Discovered in 1930 and named 
for its ability to precipitate C-lipopolysaccharide (Tillett and Francis 1930), which is a bacterial 
endotoxin of the polysaccharide capsule of Streptococcus pneumonia, CRP binds 
phosphocholine (PCh) that is exposed on the surface of pathogenic bacteria and damaged host 
cells.  The plasma half-life of CRP is about 19 hours (Vigushin et al. 1993); furthermore, long-
term elevated levels of CRP reflect an increased risk of atherosclerosis (Chang et al. 2002; 
Venugopal et al. 2002; Danenberg et al. 2003; Jialal et al. 2004; Paul et al. 2004; Agrawal et al. 
2010), cardiovascular disease (Verma and Yeh 2003; Clearfield 2005; Yaron et al. 2006; Yosef-
Levi et al. 2007), and diabetes (Pradhan et al. 2001; Dehghan et al. 2007).  The American Heart 
Association and the Centers for Disease Control and Prevention recommend its use as a clinical 
marker for inflammation and for cardiovascular disease (Kimberly et al. 2003; Pearson et al. 
2003; Kilpatrick and Bunk 2009). 
 Soluble, globular CRP monomers (Figure 1.4) associate via electrostatic interactions into 
a pentamer (Figure 1.5) with a planar pentagonal quaternary ring structure and a central pore; 
furthermore, this makes CRP a member of the pentraxin family of acute phase pattern 
recognition receptors.  The CRP pentamer has 2 opposing faces of distinct function.  The 
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recognition face (Figure 1.5a) binds PCh in a Ca
2+ 
dependent manner and each of the 5 subunits 
contains binding sites for 2 Ca
2+
 ions that complete another binding site by conferring high 
affinity for the negative head group of 1 PCh molecule (Thompson et al. 1999).  Other possible 
ligands include chromatin, fibronectin, histones, laminin, phosphoethanolamine, ribonuclear 
proteins, oxidized LDL (oxLDL) and the oxLDL receptor LOX-1 (Szalai et al. 1999; Black et al. 
2003; Fujita et al. 2009; Shih et al. 2009; Singh et al. 2012).  The globular head of C1q, a 
complement component, binds to the central pore of CRP on the effector face (Figure 1.5b) 
(Gaboriaud et al. 2003).   
 
 
Figure 1.4:  CRP Monomer.  The tertiary backbone structure of the globular CRP monomer is 
shown from (A) the recognition face or (B) a side view.  On the backbone ribbon, beta sheet 
structures appear in aquamarine and alpha helices appear in red.  Ca
2+
 ions and PCh molecules 
appear as space-filling models colored by atom where calcium = green, carbon = gray, nitrogen = 
blue (obscured), phosphate = orange, and oxygen = red.  Images were generated with Accelrys 
Discovery Studio 3.1 using the crystal structure of pentameric CRP (PDB ID: 1B09). 
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Figure 1.5:  CRP Pentamer.  The pentameric form of CRP is shown from (A) the recognition 
face and (B) the effector face.  Backbone ribbon structures appear inside space-filling models 
that illustrate the distribution of charge, where positive charge appears in blue and negative 
charge appears in red.  Ca
2+
 ions appear in yellow and PCh molecules appear in green, with the 
phosphate head groups of PCh oriented toward the Ca
2+
 ions.  Images were generated with 
Accelrys Discovery Studio 3.1 using the crystal structure of pentameric CRP (PDB ID: 1B09). 
 
Pentameric CRP forms 2-dimensional arrays bound to PCh on the cell surface and these 
arrays bind the globular head domains of C1q in a fashion similar to C1q cross-linking to Fc 
domains of immune complexes; furthermore, C1q cross-linking with either Fc or CRP can 
activate the complement cascade.  CRP-mediated C1q recruitment and complement activation 
depend only on the exposure of PCh instead of antigen recognition, although only complement 
components C1-C4, but not C5-C9, are activated in response to CRP (Thompson et al. 1999; 
Black et al. 2004).  Complement components C1-C4 form the classical pathway of complement 
activation and result in macrophage phagocytosis of opsonized target cells.  Because CRP-
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mediated complement activation does not activate C5-C9, membrane attack complexes (MACs) 
do not assemble or cause target cell lysis.  
 CRP has other immune-related functions in addition to the activation of complement, 
with both pro- and anti-inflammatory results; however, the net in vivo effects of CRP on 
inflammation are unclear and may be context dependent (Tilg et al. 1993; Heuertz et al. 1994; 
Ahmed et al. 1996; Szalai et al. 1999; Mold et al. 2002; Black et al. 2004).  CRP can be cleaved 
by HNE into protein fragments that induce neutrophil apoptosis in vitro (Kakuta et al. 2006) and 
this may help to limit neutrophil longevity and activity at sites of inflammation.  Human CRP, 
either administered or expressed in recombinant form, shows protective effects in experiments 
using murine models of lung inflammatory diseases (modeled by induced alveolitis) (Heuertz et 
al. 1994; Ahmed et al. 1996), multiple sclerosis (modeled by mouse allergic encephalomyelitis) 
(Szalai et al. 2002), and systemic lupus erythematosus (SLE) (Du Clos et al. 1994; Szalai et al. 
2003; Russell et al. 2004).   
 Much research suggests that CRP, which is known to localize in atherosclerotic lesions, 
may have functions related to atherosclerosis; however, the net effects on lesion and plaque 
formation are uncertain.  While CRP does not normally bind native LDL (Chang et al. 2002; 
Taskinen et al. 2002; van Tits et al. 2005), it has been shown, in vitro, to bind immobile 
aggregates of LDL (de Beer et al. 1982; Fu and Borensztajn 2002; Agrawal et al. 2010) as well 
as LDL that has been either enzymatically modified or chemically oxidized into 
proatherosclerotic forms (Bhakdi et al. 1999; Agrawal et al. 2010; Chang et al. 2002).  CRP 
binds enzymatically modified LDL at neutral pH and this affinity increases with increasing 
acidity (Bhakdi et al. 1999; Taskinen et al. 2002; Biró et al. 2007; Singh et al. 2008a).  
Controversy exists regarding the affinity of CRP for oxidized LDL (oxLDL).  While it has been 
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shown that CRP binds oxLDL under acidic conditions (Singh et al. 2009) and some studies 
demonstrate the same at physiological pH (Chang et al. 2002; van Tits et al. 2005), other work 
indicates that CRP and oxLDL do not readily associate in a physiologically relevant environment 
(Taskinen et al. 2002; Ji et al. 2006). 
Some evidence indicates that CRP may opsonize LDL particles, resulting in the 
phagocytosis of LDL by macrophages, which turns them into plaque-forming foam cells (Bhakdi 
et al. 1999; Zwaka et al. 2001).  Several other studies also support the hypothesis that CRP 
enhances LDL uptake by macrophages and foam cell formation (Fu and Borensztajn 2002; 
Verma et al. 2002; van Tits et al. 2005; Singh et al. 2008b).  In other studies whose results 
suggest that CRP may actually prevent foam cell formation, CRP-LDL complexes did not 
convert macrophages into foam cells (Singh et al. 2008a) and the presence of CRP increased 
LDL degradation by macrophages (Mookerjea et al. 1994).  Unfortunately, the effects of CRP on 
atherosclerosis have not been elucidated in vivo because CRP displays inconsistent effects on 
disease progression in studies of animal models of atherosclerosis (Paul et al. 2004; Hirschfield 
et al. 2005; Reifenberg et al. 2005; Schwedler et al. 2005; Trion et al. 2005; Tennent et al. 2008; 
Torzewski et al. 2008; Agrawal et al. 2010).   
It is proposed that increased acidity causes conformational changes in the CRP pentamer 
that enable it to bind oxLDL and that this may have in vivo significance in the microenvironment 
of atherosclerotic lesions (Singh et al. 2012).  Similarly, researchers also suggest that the failure 
of animal models of atherosclerosis to yield significant results in response to human CRP is due 
to species-specific differences in this microenvironment (Singh et al. 2012).  Recombinant CRP 
E42Q, a single amino acid substitution variant, has been expressed in Chinese hamster ovary 
(CHO) cells and found to bind oxLDL with improved affinity at higher pH, likely by increasing 
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pentamer flexibility due to the disruption of the salt bridge between Glu 42 of each CRP subunit 
and Lys 119 of the adjacent subunit (Singh et al. 2012).  Because of the additional flexibility and 
improved oxLDL affinity, the E42Q variant may provide a useful tool to overcome the current 
issues with in vivo studies of the effects of CRP-LDL complex formation on atherosclerosis in 
animal models.  This could help determine the net effects of CRP on atherosclerotic progression.  
If net protective roles against plaque formation are discovered, then recombinant CRP variants 
may even have therapeutic value in the treatment of atherosclerosis.   
Because CHO cells suffer from many of the drawbacks of other mammalian recombinant 
expression platforms, production times and total yields of CRP E42Q may be insufficient to 
provide enough protein for studies in animal models.  By producing CRP and variants like CRP 
E42Q in a recombinant protein expression system, larger quantities of these proteins may be 
generated more rapidly and with less cost, thus facilitating further studies of CRP binding 
interactions with LDL and other clinically relevant substrates.  Human CRP has been expressed 
in large quantities in E. coli and found to be functionally indistinguishable from native CRP 
(Tanaka et al. 2002); however, purified recombinant CRP from E. coli can retain endotoxin 
contaminants unsuitable for in vivo animal studies.  The human protein was recently also 
expressed in P. pastoris for mass spectrometry studies; however, it was found to contain the 
additional N-terminal amino acid sequence EAEA, a result of incomplete processing to remove 
α-mating factor at the kexin cleavage site (Kilpatrick et al. 2012).  While these additional amino 
acids did not adversely impact their efforts to improve standardization of CRP assays, the use of 
recombinant CRP for animal studies of atherosclerosis requires proteins without such inadvertent 
differences.   
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Chapter 4 shows the use of P. pastoris for secreted expression of human wild type CRP 
as a correctly folded, functional pentamer with yields in excess of 3.5 mg/L in growth media.  
The substitution variant CRP E42Q was also expressed, at over 1.5 mg/L.  Recombinant CRP 
and CRP E42Q were identified and quantified by ELISA using anti-CRP antibodies.  Wild type 
CRP and E42Q were PCh affinity purified for comparison to native human CRP.  Purified wild 
type CRP was characterized by SDS-PAGE under reducing conditions and found to exist in 2 
distinct monomeric forms of slightly different mass.  These could not be separated from each 
other despite the use of PCh affinity chromatography, anion exchange, and gel filtration and both 
forms were labeled by CRP-specific antibodies on a Western blot.  This result is possibly an 
anomaly of the specific yeast clone that was selected during the screening process and that other 
transformants containing the same insertion cassette may express CRP in only the correct form.  
Further investigation is warranted to solve these problems and generate recombinant CRP 
suitable for in vivo animal studies.   
 
Specific Aims 
Aim 1: Express functional recombinant human enteropeptidase light chain (hEPL) with amino 
acid substitutions to characterize and modify the contributions of residues 96 and 174 to 
the extended substrate specificity of the enzyme. 
Aim 2: Express the functional recombinant neutrophil serine proteases (NSPs) human neutrophil 
elastase (HNE) and human neutrophil cathepsin G (CatG) with intact C-terminal peptide 
tails. 
Aim 3: Express the functional pentamer of native human C-reactive protein (CRP) and the 
substitution variant CRP E42Q.  
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Abstract 
The serine protease enteropeptidase exhibits a high level of substrate specificity for the 
cleavage sequence DDDDK~X, making this enzyme a useful tool for the separation of 
recombinant protein fusion domains.  In an effort to improve the utility of enteropeptidase for 
processing fusion proteins and to better understand its structure and function, two substitution 
variants of human enteropeptidase, designated R96Q and Y174R, were created and produced as 
active (>92%) enzymes secreted by P. pastoris with yields in excess of 1.7 mg/Liter.  The 
Y174R variant showed improved specificities for substrates containing the sequences DDDDK 
(kcat/KM = 6.83 x 10
6
 M
-1
 sec
-1
) and DDDDR (kcat/KM = 1.89 x 10
7
 M
-1
 sec
-1
) relative to all other 
enteropeptidase variants reported to date.  BPTI inhibition of Y174R was significantly decreased. 
Kinetic data demonstrate the important contribution of the positively charged residue 96 to 
extended substrate specificity in human enteropeptidase.  Modeling shows the importance of the 
charge-charge interactions in the extended substrate binding pocket. 
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Introduction 
Enteropeptidase (EC 3.4.21.9), originally named enterokinase, is a trypsin-like serine 
protease that activates pancreatic digestive enzymes in the duodenum
1-7
.  The proteolytically 
active light chain has high selectivity for the sequence DDDDK (D4K)
8,9
.  Physiologically, 
enteropeptidase removes the N-terminal pro-peptide of trypsinogen by cleaving the sequence 
D4K~IVGG to activate trypsin.  Genetic deficiencies of enteropeptidase have been reported in 
two families with symptoms of intestinal malabsorption, diarrhea, and growth failure, revealing 
the importance of human enteropeptidase (hEP) in the digestive process
10,11
.  Inhibitors of 
enteropeptidase have been designed and tested in a murine model to evaluate their efficacy as 
anti-obesity drugs
12
. 
Although some non-specific cleavages have been reported for this enzyme
6,13-16
, the high 
selectivity of enteropeptidase light chain (EPL) for the sequence D4K~X makes it useful as a 
biotechnological tool for site-specific separation of recombinant fusion protein domains
17,18
.  
Recombinant bovine enteropeptidase light chain (rbEPL) has been expressed in Pichia 
pastoris
19,20
, Saccharomyces cerevisiae
21
, and Escherichia coli
18,22,23
.  The monomeric rbEPL 
from E. coli proved superior to the native heterodimeric bEP at cleaving fusion proteins
18
.  
Human EPL has greater catalytic efficiency compared to bovine EPL for D4R~X and D4K~X 
substrates
24,25
 and recombinant human enteropeptidase light chain (rhEPL) was shown to have a 
10-fold higher specificity constant (kcat/KM) for the D4K~X sequence than bEPL
26
. 
The x-ray crystal structure (PDB code: 1EKB) for bEPL in complex with the inhibitor 
VD4K-chloromethane was used in conjunction with rbEPL variants from a baculovirus 
expression system to reveal the critical role of K99 (chymotrypsinogen numbering system) in the 
S2-S4 (Schechter-Berger system)
27
 extended binding site that interacts with Asp P2-P4 substrate 
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residues
27,28
.  A recent study used the human-to-bovine substitutions R96K and K219Q to shift 
the catalytic properties of rhEPL to more closely parallel bEPL, demonstrating additive 
contributions of positive residues R96 and K219 to improved extended specificity
29
.  They 
constructed in silico models of hEPL based on the bEPL x-ray structure
28
 and proposed that R96 
may shield the P2 residue from the solvent better than K96 and that K219 may form salt bridges 
with Asp-P3 and Asp-P5
29
.  Others created, in E. coli, a Y174R variant of bEPL that showed an 
approximate four-fold improvement in specificity toward the GD4K~IVGG substrate due to 
proposed salt bridges by R174 with Asp-P3 and Asp-P4
22
.  Recently, a supercharged rhEPL 
(rhEPLsc) was created in E. coli to improve enzyme solubility and refolding yields
30,31
 and an x-
ray crystal structure of this mutant was obtained (PDB code: 4DGJ)
28,30,31
. 
In an effort to improve the utility of rhEPL for processing fusion proteins and to better 
understand the structure and function of hEPL, two rhEPL variants were created and produced as 
active enzymes secreted by P. pastoris.  Kinetic analyses employed synthetic D4K and D4R p-
nitroanilde (D4K-pNA and D4R-pNA) substrates and the N-α-carbobenzyloxy-L-lysine-
thiobenzyl ester (Z-Lys-SBzl) substrate for comparison with other reports.  Potential Asn-linked 
glycosylation sites were mutated to Gln to yield non-glycosylated proteins.  In one variant, 
arginine was replaced with glutamine at position 96 to create R96Q; furthermore, the kinetic 
properties of this variant in comparison with others suggests that the human R96 residue 
influences extended substrate affinity through charge-dependent interaction with Asp-P2.  In the 
second variant (Y174R), tyrosine at residue 174 was replaced with arginine, which has been 
shown to improve the specificity in rbEPL
22
.  The human Y174R enzyme shows the highest 
specificity for the Asp4 motif of any EPL variant reported to date. 
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Results 
Protein Engineering and Molecular Cloning 
 The amino acid sequences for the variants R96Q and Y174R were designed based on the 
sequence of native hEPL (Figure 2.1).  Due to the tendency of P. pastoris to hyper-glycosylate 
secreted proteins
32-36
, the conservative amino acid substitutions N75Q, N113Q, N135Q, and 
N175Q were used to disrupt four potential Asn-linked glycosylation sites in both R96Q and 
Y174R (Figure 2.1).  The Furin-like protease kexin (Kex2) of the Golgi apparatus in P. pastoris 
can cleave dibasic sequences such as KR~X
37
.  The substitution R98Q was incorporated into 
both R96Q and Y174R variants to eliminate a potential internal kexin cleavage site (Figure 2.1), 
supported by data that an R98A substitution does not reduce the activity of bEPL
28
.  DNA coding 
for the human R96Q and Y174R mutants was commercially codon-optimized for expression in 
P. pastoris, synthesized, and cloned into the pPICzα A plasmid for secreted expression.  
Plasmids encoding R96Q or Y174R were used to transform the X-33 strain of P. pastoris and the 
most productive clones were identified in a screening protocol.  During secretion, the Kexin 
protease removes α-mating factor via cleavage of the sequence KR~IVGG, resulting in secretion 
of active R96Q or Y174R variants.  Approximately 1.7 mg/L of active R96Q and 2.2 mg/L of 
active Y174R, as estimated by Z-Lys-SBzl activity, were expressed in 5 L batches of bioreactor 
fermentation.  Untransformed X-33 P. pastoris do not secrete enzymatic activity for the Z-Lys-
SBzl substrate. 
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Figure 2.1:  EPL Sequence Alignment.  Human and bovine EPL aligned with human R96Q and 
Y174R variants.  All engineered substitutions appear in bold and residues 96 and 174 are labeled 
with stars.  Asn-to-Gln substitutions (bent arrows) disrupt four potential Asn-linked 
glycosylation sties.  The substitution R98Q (dot) eliminates one possible kexin cleavage site.  
Serine protease active site residues (triangles) are also indicated. 
 
Purification 
Both enzymes were recovered from culture media by affinity chromatography using the 
reversible, Kunitz-type protease inhibitor, Soybean Trypsin Inhibitor (STI).  The R96Q and 
Y174R variants were purified 1352-fold and 969-fold, respectively, from fermentation media 
(Table 2.1).  Although the total protein recoveries of purified R96Q and Y174R were similar, the 
total and specific activities were unexpectedly low for Y174R (Table 2.1).  Assays during 
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purification were in the absence of CaCl2 or Triton X-100, which were subsequently found to 
enhance the activity of Y174R consistent with a report on solubility problems with recombinant 
hEP
30
.   
 
 
 
 
Subsequent kinetic analyses including 0.02 mM CaCl2 and 0.01% Triton X-100 show that 
both variants have similar KM and kcat values for Z-Lys-SBzl (Table 2.2), suggesting that Y174R 
is less soluble than R96Q.  The single-step STI affinity purification yielded highly purified 
enzymes (Figure 2.2a) and the A280-based concentration estimates were confirmed to within 8% 
by active site titration
38
.   
 
Identity Confirmation and Stability Analyses
 
 The purified recombinant enzymes were analyzed by SDS-PAGE (Figure 2.2a), 
confirming high levels of purity at the predicted molecular weight of 26 kDa for non-
glycosylated rhEPL.  Western blot analysis (Figure 2.2b) further confirms the identities of the 
rhEPL variants using a monoclonal antibody against bEPL with non-glycosylated rbEPL as a 
positive control.  Both substitution variants selectively cut an enteropeptidase cleavage control 
protein (CCP; EMD Millipore) with the same cleavage pattern as observed for Tag*off™ 
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positive control enzyme (Figure 2.2c).  Tag*off™ is a non-glycosylated recombinant hEPL 
(EMD Millipore).  
 
 
 
Figure 2.2:  Molecular Characterization of Purified EPL Variants.  (A) SDS-PAGE shows 
high purity and correct mass (~26 kDa) for non-glycosylated enteropeptidase variants R96Q and 
Y174R.  (B) Monoclonal antibody against bEPL also labels human variants R96Q and Y174R by 
Western blot.  (C) Cleavage assay shows that R96Q and Y174R variants cleave the CCP like 
Tag*Off™. 
 
Over the course of five days, Tag*off™, R96Q, and Y174R were evaluated for stability 
at 37 °C in 100 mM Tris, 0.02 mM CaCl2, 0.01% Triton X-100, pH = 8.0.  Tag*off™ and R96Q 
had half-lives longer than one week (16 days and 9 days, respectively); however, the Y174R 
substitution reduced the half-life to 48 hours (Figure 2.3).  Residue R174 may provide a target 
for EPL autolysis.  All of the enzymes showed long-term stability in low pH storage buffers at  
+4 °C and -20 °C. 
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Figure 2.3:  Enzyme Stability Assay.  Tag*Off™ (diamonds) has an estimated half-life of 16 
days.  R96Q (squares) has an estimated half-life of 9 days.  Y174R (circles) has an estimated 
half-life of 48 hours.  Error bars show standard deviation of triplicate data.  Regression analyses 
were fit to the equation ½ = e
-kt
. 
 
Kinetic Analyses 
 The Michaelis Constant KM, the catalytic rate constant kcat, and the specificity constant 
kcat/KM were evaluated for Tag*off™, R96Q, and Y174R using the synthetic peptide substrates 
Z-Lys-SBzl, GD4K-pNA, and GD4R-pNA (Table 2.2).  These assays were conducted in 100mM 
Tris, 0.02 mM CaCl2, 0.01% Triton X-100, 10% DMSO, pH = 8.0.  CaCl2 enhances EPL activity 
at the 0.02 mM concentration
26
.  NaCl was excluded because it has been shown to reduce EPL 
activity for GD4K-na
26.  Due to the limited supply of Tag*off™, the stock concentration of 
active Tag*off™ could not be determined by active site titration; consequently, all Tag*off™ 
kcat values reported here are estimates based on the averages of the values for the R96Q and 
Y174R variants, which are very similar (Table 2.2); furthermore, the estimate reported here for 
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Tag*off™ with GD4K-pNA is similar to the kcat reported elsewhere for hEPL with the substrate 
GD4K-na
26
. 
 
 
 
 For the single residue substrate Z-Lys-SBzl, no statistically significant differences were 
observed among the KM values; likewise, the kcat value for R96Q is only 1.1 times that for 
Y174R (P<0.05) (Table 2.2).  The comparison of kcat/KM ratios reveals that R96Q cleaves Z-Lys-
SBzl about 1.2 times as efficiently as either Tag*off™ (P<0.05, estimated) or Y174R (P<0.05) 
(Table 2.2).  The Y174R variant and Tag*off™ do not have statistically different kcat/KM values. 
For the substrate GD4K-pNA, the enzymes behave very differently.  The Y174R variant 
shows the smallest KM for this substrate (Table 2.2).  The KM for Tag*off™ is 1.6 times larger 
than for Y174R (P<0.01) (Table 2.2).  With the weakest affinity for GD4K-pNA, R96Q has a KM 
that is 9.3-fold greater than Tag*off™ (P<0.0005) and 15.5-fold greater than the Y174R variant 
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(P<0.0005) (Table 2.2).  The kcat of R96Q was 1.2-fold that of Y174R (P<0.005) (Table 2.2).  
The single amino acid substitution Y174R improved the catalytic efficiency for the GD4K-pNA 
substrate by 1.5-fold compared to Tag*off™ (P<0.01, estimated) (Table 2.2, Figure 2.4).  The 
specificity of R96Q for D4K-pNA showed only 12% of the value for Tag*off™ (P<0.0001, 
estimated) and only 8% of the Y174R result (P<0.0001) (Table 2.2, Figure 2.4).  Compared to 
100 mM Tris HCl, pH = 8.0, the addition of 0.02 mM CaCl2 and 0.01% Triton X-100 improved 
the specificity constants of R96Q and Y174R by 6 times and 20 times, respectively, for GD4K-
pNA. 
 
 
Figure 2.4:  Specificity Constants.  Specificity constants of Tag*Off™, R96Q, and Y174R for 
the extended substrates GD4K-pNA and GD4R-pNA are shown.  All values are mean average ± 
standard deviation, as listed in Table 2.2.  P < 0.005 for all * and ** comparisons. 
 
 KM values for GD4R-pNA were lowest for Y174R, followed by Tag*off™ at 2.4 times 
Y174R (P<0.005) and then R96Q at 6.9 times Y174R (P<0.001) (Table 2.2).  As with the other 
two synthetic substrates, the kcat values of R96Q and Y174R are very similar.  The kcat/KM 
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specificity constant of Y174R for the GD4R-pNA substrate is 2.6 times that of Tag*off™ 
(P<0.005, estimated) and 8-fold that of R96Q (P<0.005) (Table 2.2, Figure 2.4).  The kcat/KM for 
Tag*off™ is 3 times that of R96Q (P<0.005, estimated) (Table 2.2, Figure 2.4).  Compared to 
100 mM Tris HCl, pH = 8.0, the addition of 0.02 mM CaCl2 and 0.01% Triton X-100 improved 
the specificity constants of R96Q and Y174R for GD4R-pNA by 6.8 times and 28 times, 
respectively. 
Comparison of the relative efficiencies of each enzyme for the extended peptide synthetic 
substrates reveals that the GD4R-pNA sequence is preferred over GD4K-pNA by all variants, 
especially for Y174R, by 2.8 times (P<0.01) (Table 2.2, Figure 2.4).  The Tag*off™ enzyme 
only showed 1.3 times greater selectivity for GD4R-pNA (P<0.005) compared with GD4K-pNA, 
although the KM was reduced by 42% (Table 2.2, Figure 2.4).  While R96Q had the lowest 
specificity constants with either of the extended peptide substrates, its preference for GD4R-pNA 
was 4.3 times that of GD4K-pNA (P<0.005) (Table 2.2, Figure 2.4). 
The substitution Y174R significantly decreases the binding affinity for the inhibitor BPTI 
(Table 2.3).  The inhibition equilibrium constant, Ki, is 4 times larger for Y174R (P<0.0001) 
than for Tag*off™ and 3.6 times larger (P<0.0001) than for R96Q (Table 2.3).  The R96Q 
substitution did not significantly change the Ki from that of Tag*off™ (Table 2.3). 
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Discussion 
The extended substrate binding pocket of EPL can be thought of as a five-walled cage 
where residues 96, 99, 174, and 219 form walls 1-4 (Figure 2.5), with the active site (S195) and 
the S1 specificity pocket (D189) forming the floor.  The open fifth wall and the open ceiling of 
the cage allow the substrate to enter.  In all variants, “wall 2” (K99) and the “floor” are required 
for D4K specificity
28
.  Added specificity comes from the properties of the other walls.  In bEPL, 
“wall 1” is K96, “wall 3” is Y174, and “wall 4” is Q219 (Figure 2.5a).  The positive charge of 
K96 has been shown to improve specificity
28
; however, Y174 contributes only a weak hydrogen 
bond between the tyrosine hydroxyl group and the carboxyl side chain of Asp-P3
28
.  In the study 
of the E. coli variant rbEPL Y174R (Figure 2.5b), the presence of the ε-guanidino group of R174 
on “wall 3” of the cage was shown to improve extended substrate specificity and was proposed 
to form a salt bridge with Asp-P3
22
.  According to the x-ray crystal structure of bEPL (Figure 
2.5a), Q219 side chain does not interact with the substrate in any way, extending away from the 
binding site instead. 
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Figure 2.5:  Electrostatic Models of EPL Extended Binding Pockets.  Proposed electrostatic 
models show EPL binding pockets with bound D3K substrate.  Positively charged (blue) residues 
(green labels) improve binding affinity for Asp P2-P4.  Negative charges are red.  (A) Bovine 
EPL (PDB Code: 1EKB).  (B) Bovine EPL with Y174R substitution.  (C) Human EPL (by 
substitution of PDB model 4DGJ).  (D) Human EPL with Y174R substitution.  (E) Supercharged 
human EPL (PDB code: 4DGJ).  (F) Human EPL with R96Q substitution. 
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The improved specificity of hEPL over bEPL can be attributed in part to differences in 
two of the cage walls (Figure 2.5a and 2.5c) and in part to species-specific differences in the 
stability of the active site and specificity pocket
29
.  First, amino acid substitution by others has 
shown that R96 stabilizes Asp-P2 better than K96
29
.  Second, another substitution by the same 
group has also shown that K219 improves the substrate specificity of rhEPL compared to Q219, 
especially in conjunction with R96
29
.  The positively charged K219 side chain amino group may 
by attracted toward the binding site in the presence of Asp-P3 in hEPL
29
 to form “wall 4” (Figure 
2.5c, 2.5d, and 2.5f) whereas Q219 and D219 side chains extend into the solvent in the crystal 
structures of bEPL
28
 (Figure 2.5a and 2.5b) and rhEPLsc
34
 (Figure 2.5e). 
The human Y174R variant presented here combines the improved specificity of the 
bovine Y174R substitution
22
 with the positive influences of residues R96 and K219
29
 in the 
human enzyme.  The result is the novel human Y174R (Figure 2.5d) with improved extended 
substrate specificity relative to previously reported rEPL variants.  This Y174R enzyme may 
prove advantageous for the separation of recombinant protein fusion constructs.  Although 
Y174R has only a slightly better specificity than Tag*off™ for the D4K sequence, Y174R 
displays a very high specificity constant for the D4R sequence (Table 2.2, Figure 2.4).  This 
reduces nonspecific cleavage by Y174R in the presence of excess fusion protein if the D4R linker 
is employed.  The shorter enzyme half-life of Y174R may be due to autolysis at R174.  Although 
poor stability is typically undesirable in enzymes, the limited half-life of Y174R under catalytic 
conditions (pH = 8.0, 37 °C) may actually contribute to a reduction of non-specific substrate 
cleavage relative to native EPL. 
The R96Q variant generated during this project reveals that the absence of positive 
charge at position 96 reduces the catalytic efficiency by 94% relative to Tag*off™ for D4K and 
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by 68% relative to Tag*off™ for D4R (Table 2.2, Figure 2.4).  Others have shown that the K96A 
substitution in rbEPL reduces its specificity by approximately 80% of native bEPL for GD4K-
na
28
.  It has also been previously shown that the human-to-bovine substitution rhEPL R96K 
reduces its specificity by only about 6% relative to rhEPL
29
.  These data suggest that the positive 
charge of residue 96 contributes significantly to the substrate specificities of all EPL variants, 
despite crystallographic evidence suggesting that K96 in bEPL does not coordinate with Asp-
P2
28
. 
Examination of an x-ray crystal structure of the β-trypsin + BPTI complex (PDB code: 
3OTJ)
39
 aligned with the structure of EPL reveals that BPTI residue Arg39 lies in close proximity 
to EPL residue 174.  As a result, an electrostatic repulsion likely occurs, accounting for the 
approximately 5-fold increase in the Ki of Y174R for BPTI.   
Non-glycosylated recombinant human enteropeptidase variants Y174R and R96Q were 
easily expressed into the growth media of P. pastoris as properly folded active enzymes.  Both 
enzymes were highly purified by chromatography on immobilized STI.  The Y174R variant 
displayed increased specificity for the GD4R-pNA substrate relative to a commercial sample of 
recombinant human enteropeptidase (Tag*off™).  The potential utility of a D4R linker between 
fusion proteins
24,25
 is thus amplified by the use of Y174R.  The kinetic properties of R96Q 
demonstrate the importance of R96 to the binding of extended peptide substrates.  
 
Materials and Methods 
The hEPL amino acid sequence was taken from NCBI Ref. Seq. NP_002763.2.  DNAs 
were codon-optimized and synthesized by different companies; R96Q by GenScript and Y174R 
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by DNA 2.0.  The recombinant human EPL named Tag*off™ and a cleavage control protein 
(CCP) were products of EMD Millipore.  
 
Molecular Cloning 
The DNA sequences for R96Q and Y174R were cloned into the pPICzα A plasmid (Life 
Technologies).  The linearized vectors were used to transform X-33 strain P. pastoris (Life 
Technologies) by electroporation.  Transformants were selected on YPDS agar plates with 100 
µg/mL Zeocin and 100 µg/mL Ampicillin.  Selected colonies were grown in 12-well microtiter 
plates as 2 mL cultures in synthetic minimal medium (SMM) (10 g/L MSG, 2.5 g/L (NH4)2SO4, 
100 mM KH2PO4 at pH = 5.0, 13.4 g/L YNB, and 0.4 mg/L biotin) containing 0.5% methanol
40
.  
Cultures were grown for four days at room temperature with daily addition of 0.5% methanol.  
Culture supernatants were tested for enteropeptidase activity using the synthetic substrate Z-Lys-
SBzl and activities were normalized to wet cell pellet weights (WCW) for selection of the best 
expressers.  
 
Fermentation 
 Cultures were grown using the strategy in the Life Technologies Pichia Fermentation 
Process Guidelines, with some modification.  Basal salts medium (BSM) contained 26.7 mL/L 
H3PO4, 18.2 g/L K2SO4, 14.9 g/L MgSO4, 4.13 g/L KOH, 40 g/L glycerol and was modified by 
adding 10 g/L MSG and 2.5 g/L (NH4)2SO4
40
.  CaSO4 was omitted to reduce the formation of 
insoluble calcium phosphates.  BSM was supplemented with PTM4 trace elements
41
.  Antifoam 
204 (0.5 mL/L) was used to prevent foaming.  Fermentation occurred at pH at 5.0 and pure O2 
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was used to maintain the dissolved O2 content (dO2) at 35% by regulating the impeller speed.  
Culture density and protein accumulation were monitored daily.   
 
Purification 
Culture supernatants, adjusted to pH = 8.0, were centrifuged and filtered through glass 
fiber pre-filters and 0.45 µm PE filters.  Enzymes were affinity purified at pH = 8.0 on an 
agarose column with immobilized Soybean Trypsin Inhibitor (STI).  The wash buffer contained 
50mM Tris, 0.5 M NaCl, pH = 8.0 while 50 mM acetic acid, 0.5 M NaCl, pH = 3.5 was used for 
protein elution.  Active fractions (Z-Lys-SBzl) were pooled and concentrated by ultrafiltration on 
a 10K MWCO membrane (Millipore) and stored in 100 mM glycine, pH = 3.0. Active site 
titrations of R96Q and Y174R were performed with 4-methylumbelliferyl-p-guanidinobenzoate 
(MUGB)
38
.  
 
SDS-PAGE and Western Blotting 
SDS-PAGE was performed with 12% (Figure 2.3a and 2.3b) or 4-12% (Figure 2.3c) 
NuPAGE gels using MOPS SDS running buffer (Life Technologies) and stained with NuBlu 
Coomassie stain (NuSep).   Western blot on PVDF was blocked for 1 hour in TBST + 1% BSA 
at 20 °C, then reacted with 0.1 µg/mL of a mouse monoclonal antibody against bEPL (GenScript) 
in TBST.  After washing with TBST, the blot was then incubated for 1 hour with HRP-
conjugated goat anti-mouse antibody (0.08 µg/mL) in TBST (Pierce), washed in TBST, and 
visualized using Super Signal West Pico ECL (Pierce).  Images were captured and processed 
using a GBox (Syngene). 
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Cleavage of CCP 
 CCP was incubated with Tag*off™, R96Q, or Y174R enzyme at 37 °C in 20 mM Tris-
HCl, 50 mM NaCl, 2 mM CaCl2, pH = 7.4 (provided with Tag*off™).  At 2 hours and 6 hours, 
samples were collected and frozen (-20 °C) prior to SDS-PAGE analysis.  
 
Stability Assay 
 Enzymes were incubated for five days at 37 °C in 20 mM Tris-HCl, 50 mM NaCl, 2 mM 
CaCl2, pH = 8.0 and daily samples were stored at -20 °C prior to assays in 300 µM Z-Lys-SBzl, 
100 mM Tris, 0.02 mM CaCl2, 0.01% Triton X-100, 10% DMSO, 1 mM DTNB, pH = 8.0.  
 
Kinetic Assays 
All enzyme activity assays were conducted in 100 µl format on a 96-well microtiter plate 
reader at 25 °C ± 0.5 °C.  All substrate stocks were freshly dissolved in DMSO.  The assay 
conditions were 100 mM Tris, 0.02% CaCl2, 0.01% Triton X-100, 10% DMSO, pH = 8.0.  
Assays with 0.05-1.0 mM Z-Lys-SBzl (Sigma or Bachem) also included 1 mM DTNB
42,43
.  The 
extended peptide substrates GD4K-pNA and GD4R-pNA (LifeTein) were used at concentrations 
between 0.02-1.0 mM and 5-100 μM, respectively.  Reactions were initiated by adding enzyme 
to a 2nM final concentration into premixed buffer and substrate.  Absorbances at 410 nm were 
followed kinetically for 10 minutes.  Product extinction coefficients were 13,600 M
-1
 cm
-1 
for the 
thiobenzyl assays and 8,800 M
-1
 cm
-1
 for p-nitroaniline.  The kinetic parameters KM and kcat were 
determined by hyperbolic regression analysis of data using Hyper32 (J. Easterby, 
©
2003). 
BPTI inhibition assays were conducted in the same format and with 100 mM Tris, 0.02% 
CaCl2, 0.01% Triton X-100, 10% DMSO, pH = 8.0, containing 1mM DTNB and using 300-600 
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μM Z-Lys-SBzl as the substrate.  Here, 2 nM enzyme concentrations were premixed with 50-600 
nM BPTI and incubated at room temperature for 15 minutes prior to the addition of Z-Lys-SBzl 
to initiate the reactions.  Dixon plots were generated from the reaction velocity data to determine 
the Ki values
44
. 
 
Molecular Modeling 
Modeling was performed in Discovery Studio 3.1 (Accelrys), using bEPL (PDB code: 
1EKB) (Figure 2.5a) to create the proposed model of rbEPL Y174R (Figure 2.5b) by single 
amino acid substitution.  This side chain was repositioned by manual bond rotation, compared to 
the previously proposed position of R174
22, and its geometry was cleaned using the software’s 
Dreiding-like force field.  The structure of rhEPLsc (PDB code: 4DGJ) provided the template for 
modeling all human EPL variants in complex with the D3K substrate (taken from 1EKB).  The 
key residues R96, R174, and K219 were repositioned, as above, in comparison with previous 
reports
22,29
 to reflect possible interactions with the D3K substrate (Figure 2.5c, 2.5d, 2.5e, and 
2.5f).  Residue Q96 (Figure 2.5f) positioning could not be predicted based on currently available 
data. 
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Abstract 
 Recombinant human neutrophil elastase (rHNE) and human Cathepsin G (rhCatG) were 
expressed with intact C-terminal pro-peptide extensions in the yeast Pichia pastoris and, with 
limited success, in the yeast Kluyveromyces lactis.  Both enzymes were engineered as fusion 
proteins linked to the heme-binding domain of cytochrome B5 (CytB5) and hexahistidine 
(6xHis) tag by an enteropeptidase-cleavable linker sequence, forming protease zymogens.  Both 
full-length fusion proteins were secreted into the growth media of P. pastoris and partially 
purified by immobilized metal affinity chromatography for the 6xHis tag, furthermore, the 
partially purified enzymes displayed absorbance at 410 nm that characterizes heme-bound 
recombinant CytB5 fusion proteins.  Both rHNE and rhCatG were activated from their zymogens 
upon treatment with enteropeptidase, and the concentrations of both activities corresponded to 
the intensities of absorbance at 410 nm.  This is the first report of successful recombinant 
expression of proteolytically active HNE and hCatG in any microorganism, as well as the first 
report of the use of CytB5 as a recombinant fusion protein domain in any eukaryotic 
recombinant expression system.  Neither active enzyme was successfully purified to 
homogeneity, despite repeated attempts using multiple ion exchange chromatography and 
affinity chromatography for the specific, reversible serine protease inhibitors basic pancreatic 
trypsin inhibitor (BPTI, Trasylol®) and secretory leukocyte proteinase inhibitor (SLPI). 
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Introduction 
 The neutrophil serine proteases (NSPs) human neutrophil elastase (HNE; EC 3.4.21.37) 
and cathepsin G (CatG; EC 3.4.21.20) act in multiple ways during acute inflammatory and 
immune responses
1-3
.  Both HNE and CatG, along with a third NSP, Proteinase 3 (Pr3, 
Myeloblastin), reside in primary (azurophil) granules of neutrophils (polymorphonuclear 
leukocytes, PMNs)
4,5
 and act against pathogenic bacteria
6-10
 and fungi
11-13
, by intracellular
6,7,11,14
 
and extracellular
13,15-18
 means.  In addition to proteolytic and non-proteolytic
19-25
 antimicrobial 
properties, HNE and CatG also process various cytokines
26-28
, chemokines
29-34
, and protease 
activated receptors (PARs)
35,36
 to participate in inflammatory regulation and cell signaling
1-3
.  In 
the BRENDA enzyme database, more information and links to research articles can be found for 
HNE (http://www.brenda-enzymes.org/php/result_flat.php4?ecno=3.4.21.37) and for CatG 
(http://www.brenda-enzymes.org/php/result_flat.php4?ecno=3.4.21.20). 
Many mutations of the HNE-coding gene (ELANE) result in cyclic
37-40
 or severe 
congenital
39,41-45
 forms of hereditary neutropenia, diseases of neutrophil maturation characterized 
by reduced numbers of neutrophils in circulation and increased susceptibility to infections, and 
these mutations affect HNE activity in different ways
46
.  Chain-terminating mutations in ELANE 
have been identified, localized to the final (fifth) exon, that lead to translation of HNE lacking a 
complete C-terminus
47
 and these mutations are closely associated with severe congenital 
neutropenia (SCN)
46
; however, the roles of the C-terminus of HNE are unclear.   
All chymotrypsin-like serine proteases, including NSPs
3,48-50
, are initially translated as 
inactive precursors containing N-terminal signal sequences and activation dipeptides; however, 
the NSP precursors also possess unusual C-terminal propeptide tails of varying length that do not 
resemble each other and whose functions are not known
47,51,52
.  These tails are removed post 
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translationally by an unidentified protease and they are not required for trafficking of NSPs to 
neutrophil primary granules
1,47,53
.  HNE with an intact C-terminal tail, but not Pr3, is directed, at 
least in part, through a detour to the cell membrane, from where it is re-internalized by 
endocytosis
53
; however, it is unclear if this is also true for CatG.  HNE contains a binding site for 
the µ3a subunit of AP3 that is only exposed after removal of the C-terminal tail
54
 but it appears 
that this is not how AP3 and HNE interact during trafficking
53
.  Instead, the tetraspanin CD63 
has been shown to associate with HNE to mediate AP3-dependent granule delivery
55
, although 
the CD63 binding site on HNE has not been identified.  The roles of the C-terminal tail of CatG 
have not been investigated as thoroughly as HNE and the function of the tail is still unknown.   
Although others have previously expressed variants of HNE and CatG in mammalian 
cells
51,56-58
, active variants of these enzymes have not been expressed in sufficient quantities for 
most biochemical studies.  Recombinant variants of active HNE and active CatG containing 
intact C-terminal tails have also not been expressed and may facilitate investigations into the 
function(s) of NSP C-termini and the mechanism(s) responsible for their removal.  CatG also 
exhibits a broad, duel specificity for both trypsin- and chymotrypsin- like substrates
59,60
 that is 
attributed to the negative charge of Glu 226 (chymotrypsinogen numbering system) at the base of 
a deep, relatively hydrophobic S1 binding pocket (Schechter-Berger numbering system)
61
.  
Recombinant expression of CatG in milligram or gram quantities would enable studies of amino 
acid substitutions to affect changes in CatG substrate specificity. 
HNE and CatG were expressed successfully as secreted, recombinant fusion proteins in 
the yeast P. pastoris and secreted expression attempts were also made, with limited success, in a 
similar expression system based on the yeast K. lactis.  Both enzymes were produced with intact 
C-terminal pro-domain tails as protease zymogens whose enzymatic functions were activated by 
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the enteropeptidase (EP) -mediated removal of an N-terminal heme-binding cytochrome B5 
(CytB5) domain.  The fusion proteins also had the heme-binding properties of CytB5; exhibiting 
absorbance maxima at 410 nm that facilitated the partial purification by immobilized metal 
(Ni
2+
) affinity chromatography (IMAC) affinity for an N-terminal hexahistidine (6xHis) tag.  
Attempts to further purify the activated recombinant enzymes to homogeneity were unsuccessful 
and require further investigation. 
 
Results and Discussion 
Protein Modifications and Fusion Protein Design 
 NSP Domains and Modifications.  The recombinant HNE (rHNE) and recombinant 
human CatG (rhCatG) amino acid sequences (Figure 3.1), starting at residue Ile16 
(chymotrypsinogen numbering) and including intact C-terminal extensions, were designed from 
the known sequences of native HNE (NCBI Ref. Seq. NP_001963.1) (Figure 3.1a) and hCatG 
(NCBI Ref. Seq. NP_001902.1) (Figure 3.1b).  An N-terminal EP-cleavable linker sequence, 
DYKDDDDK, was added to each (Figure 3.1).  Conservative substitutions were made to disrupt 
potential glycosylation sites because P. pastoris often hyper-glycosylates secreted proteins
62-66
.  
In rHNE, three potential N-linked glycosylation sites were disrupted by the substitutions N72Q, 
N109Q, and N159Q; similarly, one predicted N-linked glycosylation site was disrupted in 
rhCatG by the substitution N65Q.  One potential O-linked glycosylation site was disrupted in 
rHNE by the substitution S260N; however, this created a potential N-linked glycosylation site.  
Alternatives to this substitution were considered, and this issue was resolved by the additional 
substitution T262A. 
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Figure 3.1: Amino acid sequence alignments. Alignments of (A) native HNE and engineered 
rHNE, with N-terminal EP cleavage site extension DYKDDDDK, or (B) native hCatG and 
engineered rhCatG, also with DYKDDDDK, highlight key features and differences.  The N-
terminal Ile 16 residue ( ) and the catalytic triad residues ( ) that are necessary for proteolytic 
activity, as well as the Glu 226 residue ( ) that confers trypsin-like substrate specificity, appear 
in green.  Substitution sites to disrupt potential N-linked ( ) and O-linked ( ) glycosylation 
appear in orange and purple, respectively.  Arg-to-Gln substitutions ( ) to reduce the pI and 
eliminate potential kexin cleavage sites appear in blue.  The C-terminal pro-peptide tails that are 
removed during neutrophil maturation appear in bold with red underline. 
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Both P. pastoris and K. lactis express similar furin-like kexin proteases that can cleave 
dibasic sequences such as KR~X and RR~X
67,68
.  In rHNE, the substitutions R21Q, R76Q, 
R128Q, and R178Q were used to disrupt four potential kexin cleavage sites (Figure 3.1a) and, in 
rhCatG, the substitutions R76Q, R86Q, R111Q, R114Q, R148Q, R178Q, R186Q, and R188(a)Q 
were similarly used (Figure 3.1a).  The replacement of highly basic Arg residues with Gln at 
these sites also reduced the calculated isoelectric points of both rHNE, from 9.7 to 8.7, and of 
rhCatG, from 11.9 to 10.9.  This is thought to be beneficial because it has been shown that a 
comparatively high protein isoelectric point correlates with poor expression in P. pastoris
69
. 
Cytochrome B5 Recognition and Purification Domain.  Separately, the amino acid 
sequence of a fusion domain was designed for addition to the N-terminus of the rHNE and 
rhCatG proteins.  This fusion domain consists of the soluble heme-binding domain of 
cytochrome B5 (CytB5) from Rattus norvegicus (NCBI Ref. Seq. NP_071581.1) with an N-
terminal hexahistidine (6xHis) tag for IMAC purification and antibody-based detection
70-72
.   The 
CytB5 domain has been used previously to produce, in E. coli, heme-binding recombinant 
proteins with a distinctive spectrophotometric absorbance peak at the wavelength λ = 410 
nm
71,72
.  Additionally, the CytB5 fusion decreased the pI of the secreted protein and prevented 
premature activation of the enzymes which could have been damaging to the yeast cells. 
 Fusion Protein Zymogens.  Based on the three modified amino acid sequences, three 
protein-coding genes were codon-optimized for recombinant expression in P. pastoris and K. 
lactis and synthesized as cDNAs with suitable restriction sites for subsequent plasmid 
construction.  Expression plasmids were assembled in two stages and used to successfully 
transform P. pastoris and K. lactis. 
82 
 
 
Figure 3.2:  Fusion Construct Schematics.  The multi-domain structure of the rhCatG and 
rHNE fusion constructs, starting with the N-termini on the left.  The α-mating factor yeast 
secretion signal pre-domain (yellow) directs both polypeptide chains to the secretory pathway.  
In the Golgi, the protease kexin (Kex2) cleaves the Kex2 site (blue) KR~H to remove the pre-
domain.  This exposes the N-terminal 6xHis tag (orange) of the purification and activation pro-
domain of the secreted, inactive, mature zymogen.  The cytochrome B5 domain (red) of the 
mature zymogen exists in a heme-bound state.  The treatment of these constructs with the serine 
protease enteropeptidase (EP) specifically cleaves the D4K~I peptide bond of the EP site to 
activate rhCatG and rHNE (green) by removing the pro-domain to expose the N-terminal Ile16 
of either enzyme. 
 
The fusion proteins encoded by these plasmids contain multiple domains intended to 
facilitate the expression, secretion, purification, identification, and activation of the enzymes 
rHNE and rhCatG.  The initial intracellular products of gene translation include, at their N-
termini, the yeast α-mating factor signal sequence that directs the protein for secretion and is, 
subsequently, removed by kexin in the Golgi apparatus (Figure 3.2).  The final secreted protein 
contains an N-terminal 6xHis tag and CytB5 heme-binding domain connected by the EP-
cleavable linker sequence to the rHNE or rhCatG protease domain (Figure 3.2).  The constructs 
are protease zymogens that can only be activated through cleavage of the sequence DDDDK~I 
by enteropeptidase to separate the protease domains from their fusion partners and expose the 
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native Ile16 N-termini that are necessary for the activity of all S1 clan serine proteases (Figure 
3.2)
73
. 
 
Transformation and Screening 
P. pastoris and K. lactis cells were transformed with linearized insertion cassettes 
designed to integrate into the yeast genomes by site-specific homologous recombination into the 
AOX1 transcriptional promoter of P. pastoris or the LAC4 transcriptional promoter of K. lactis.  
Positive transformed colonies from agar plates were grown in 2 mL or 10 mL cultures, 
depending on the number of transformants, under inducing conditions for four days.  After 
harvesting, culture supernatants were adjusted to pH = 8.0 and treated overnight with EP and 
then tested for rHNE or rhCatG enzymatic activity (units/mL).  The wet cell pellet mass (g/mL) 
was also determined for each culture, after which the ratio of enzymatic activity to wet cell pellet 
mass (units/g) was calculated.  Figure 3.3a shows the results for CytB5-rhCatG screening of 44 
P. pastoris transformants as an example.  The four colonies with the highest ratios were selected 
for growth in baffled flasks with equal starting culture densities, to confirm the results obtained 
in smaller volumes.  In the sample case of rhCatG, the four best colonies were #3, #27, #36, and 
#43.  Of these, #43 expressed more enzyme than #36 (not shown), which had given the best 
results in the smaller volume (Figure 3.3a). 
84 
 
 
Figure 3.3:  Screening Colonies for rhCatG.  (A) Activity (units) per gram of wet cell mass 
was calculated for 44 P. pastoris clones grown for 4 days in 2 mL cultures.  Clarified culture 
supernatants were activated with EP and tested for rhCatG activity (units/mL) using the 
chromogenic synthetic peptide substrate Suc-AAPF-SBzl.  The weight (g/mL) was determined 
for each cell pellet.  The four best clones (orange and red bars) were grown in 100 mL cultures in 
induction medium, starting at an OD600 = 1, and screened for activity (not shown), finding that 
colony #43 (red bar) expressed more activity per cell density than the others.  (B) PCR on gDNA 
extracted from yeast cell pellets confirms the presence of multiple repeat tandem copies of the 
insertion cassette in colony #43 by the appearance of the ~1 kb PCR amplification product.  
Colonies #3 and #27 also tested positive, although the bands appear very faint.  The negative 
control and #36 tested negative.  Band intensity does not correlate to the number of genomic 
inserts, due to variation in the concentration and integrity of the gDNA samples used as PCR 
templates. 
 
Because multiple recombination events can occur within a single cell of either species 
during transformation to create a multi-copy integrant, the most productive clones were screened 
by PCR to identify those containing multiple genomic copies of the insertion cassette.  Genomic 
DNA (gDNA) samples were extracted from cell pellets using glass bead disruption, 
phenol/chloroform extraction, and ethanol precipitation; furthermore, the integrity of each gDNA 
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sample was evaluated by gel electrophoresis.  Both PCR tests used primers that only amplified 
their product if two adjacent copies of the insertion cassette occurred in tandem in the gDNA.  
Results for the CytB5-rhCatG clones #3, #27, #36, and #43 are provided as an example (Figure 
3.3b).  In this instance, the clone #43 showed a clean PCR product of the correct size (~1 kb) that 
confirms clone #43 as a multi-copy integrant.  For each yeast species and each fusion protein, a 
single clone was identified by this process as the best for continued use.   
 
Protein Expression 
The most successful and heavily pursued of the CytB5-rHNE and CytB5-rhCatG fusion 
protein expression attempts occurred by fermentation of P. pastoris transformants.  Expression 
attempts in K. lactis produced only limited success, thus they were abandoned in favor of the P. 
pastoris platform.  CytB5-rHNE K. lactis fermentation produced less than 100 µg/L of EP-
activable rHNE activity against MeO-Suc-AAPV-pNA (less than 150 µg/L CytB5-rHNE); 
furthermore, neither the cells nor the culture supernatant displayed 410 nm absorbance peaks and 
no red color was visible prior to purification (below).  Bioreactor scale fermentation of CytB5-
rhCatG K. lactis was not pursued due to poor results on a small scale and the limited success of 
CytB5-rHNE.   
Clarified culture supernatants of both CytB5-rHNE and CytB5-rhCatG strains contained 
their respective activities, which were only detectable after activation with EP, but the media did 
not exhibit 410 nm absorbance peaks.  The CytB5-rHNE supernatants from successful 
fermentations of P. pastoris are estimated to have produced between 1.5 and 3.5 mg/L of EP-
activated rHNE (between 2.3 and 5.3 mg/L of CytB5-rHNE recombinant protein), as determined 
by catalytic activity for the chromogenic synthetic peptide substrate MeO-Suc-AAPV-pNA in 
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comparison to known concentrations of purified native HNE.  The CytB5-rhCatG P. pastoris 
never produced more than 200 µg/L of EP-activated enzyme (~300 µg/L of CytB5-rhCatG 
recombinant protein) in fermentation media, compared to purified native hCatG for the substrate 
Suc-AAPF-SBzl.   
During the methanol induction phase of growth, P. pastoris cultures expressing both 
CytB5 constructs developed a dark pink color distinct from the light tan normally seen in P. 
pastoris cultures.  The majority of this color was retained by cell pellets and only recoverable 
upon cell lysis.  Clarified cell lysates exhibited the dark red color and 410 nm absorbance peak 
indicative of CytB5 protein expression; however, these lysates did not display HNE or CatG 
activity before or after treatment with EP.   
 
Partial Purification and Activation: rHNE and rhCatG in P. pastoris 
 Both CytB5-rHNE and CytB5-rhCatG fusion proteins were partially purified from P. 
pastoris fermentation media using immobilized metal (Ni
2+
) affinity chromatography (IMAC) 
for the 6xHis tag; however, efficient recoveries were dependent on buffer exchange by 
ultrafiltration of fermentation media prior to purification.  Due to the heme-binding properties of 
the CytB5 domain, IMAC elution fractions containing purified fusion constructs could be 
identified by the presence of 410 nm peaks in their absorbance spectra (Figure 3.4).  Purified 
fractions of CytB5-rHNE had a distinct absorbance peak at 410 nm in addition to the expected 
280 nm absorbance peak (Figure 3.4a); furthermore, fractions with strong 410 nm absorbance 
peaks often appeared dark red-brown in color.  Purified fractions of CytB5-rhCatG contained an 
additional, stronger absorbance peak at 350 nm (Figure 3.4b) and these fractions displayed a dark 
green color believed to be attributable to a co-purified contaminant that was not successfully 
removed. 
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Figure 3.4:  Absorbance Spectra for CytB5 Fusion Protease Zymogens After Partial 
Purification by IMAC.  Partially purified (A) CytB5-rHNE exhibits the characteristic spectrum 
for purified CytB5 fusion proteins, with clear absorbance maxima at 280 nm ( ) and 410 nm ( ) 
accompanied by a visible dark red color.  (B) CytB5-rhCatG recovered by IMAC was 
contaminated with an unidentified substance that made the eluate visibly dark green instead of 
dark red, as confirmed by the additional absorbance maximum at 350 nm ( ) and the increased 
A280/A410 ratio relative to (A) CytB5-rHNE. 
 
IMAC elution fractions that contained detectable 410 nm absorbance peaks were 
activated by overnight treatment with EP.  Levels of subsequent rHNE and rhCatG activities 
increased to their maxima as functions of treatment time (data not shown) and correlated by 
fraction to the intensity of absorbance at 410 nm, but not 280 nm, suggesting the identity and 
partial purification of both enzymes, as in the examples shown (Figure 3.5), where 
approximately 600 µg of CytB5-rHNE (Figure 3.5a) and 270 µg of CytB5-rhCatG (Figure 3.5b) 
were recovered, as estimated by activity.  About 1.2 mg of CytB5-rHNE was recovered from 1 L 
of fermentation medium containing approximately 1.5 mg, an 80% recovery yield, during the 
most successful purification attempt.  Due to limited CytB5-rhCatG expression, 3.5 L of 
fermentation medium, concentrated more than 50-fold and containing about 370 µg activable 
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enzyme, was necessary to acquire the estimated 270 µg indicated above, a 73% recovery yield.  
The ratios of A410/A280 reflect the relative amount of purification by fraction. 
 
 
Figure 3.5:  IMAC elution profiles.  Profiles are shown for the partial purification of 
(A) CytB5-rHNE and (B) CytB5-rhCatG.  Absorbance at 280 nm ( ) shows total protein content 
and 410 nm ( ) shows the presence of heme-bound CytB5 fusion domain.  Bar graphs show the 
enzymatic activity in 25 µL of EP-activated fractions of (A) rHNE for MeO-Suc-AAPV-pNA or 
(B) rhCatG for Suc-AAPF-SBzl.  Enzymatic activity is proportional to absorbance at 410 nm, 
but not 280 nm.  The higher ratio of A410/A280 for CytB5-rHNE indicates greater purity 
relative to CytB5-rhCatG.   
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Figure 3.6:  SDS-PAGE and Western Blot for Partially Purified CytB5-rHNE.  CytB5-
rHNE partially purified by IMAC and activated by EP in comparison to native HNE.  (A) SDS-
PAGE under reducing conditions shows partial purification of CytB5-rHNE and activation by 
EP.  Native HNE is a mixture of three isoforms appearing between approximately 25 – 30 kDa 
that vary by glycosylation pattern.  Prominent bands appearing between 10 – 15 kDa in the 
native HNE sample correspond to fragments of autolysis and also appear in commercial 
preparations of purified native HNE.  (B) Activated rHNE, but not CytB5-rHNE, detection by 
Western blot confirms the identity of active rHNE.  The primary antibody was polyclonal rabbit 
anti-HNE IgG and the HRP-conjugated secondary antibody was polyclonal goat anti-rabbit IgG. 
The 10 kDa band in CytB5-rHNE is unidentified, but may be due to non-specific binding.  Two 
bands are labeled in the native HNE sample, showing the mature enzyme (~25 kDa) and a 
fragment of limited autolysis (< 15 kDa) as in (A).  
  
IMAC purified CytB5-rHNE from P. pastoris, with and without EP pre-treatment, were 
analyzed by SDS-PAGE and Western Blot to verify the purity, identity, and activation of the 
recombinant construct (Figure 3.6).  SDS-PAGE under reducing conditions shows the presence 
of a protein above 35 kDa that corresponds to the calculated molecular mass of 38 kDa for 
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CytB5-rHNE (Figure 3.6a); however, many other proteins of lower molecular mass also appear 
in the sample, likely products of incomplete translation or protein degradation that co-purify with 
the activable enzyme as a consequence of the N-terminal location of the 6xHis tag (Figure 3.6a).  
After overnight treatment with EP, the same sample displays a prominent band at 25 kDa (Figure 
3.6a), the calculated molecular mass of activated rHNE.  Faint bands of varying molecular mass 
in the activated rHNE sample likely correspond to inactive fragments cut by EP or HNE (Figure 
3.6a).  Purified, native HNE is a mixture of three isoforms with different glycosylation patterns 
that migrate between about 25 – 30 kDa (Figure 3.5a)74,75.  The native HNE sample also displays 
prominent bands between 10 – 15 kDa due to limited autolysis, similar to commercial 
preparations from whole blood (http://www.athensresearch.com/products/enzymes-and-
inhibitors/elastase-human-neutrophil).  
Western blotting with a rabbit anti-HNE primary polyclonal antibody and HRP-
conjugated goat anti-rabbit IgG secondary antibody labeled both native HNE and activated rHNE 
at ~25 kDa (Figure 3.6b); however, the CytB5-rHNE zymogen was not detected.  The 10 kDa 
band that appears in the CytB5-rHNE sample on the blot (Figure 3.6b) is likely due to non-
specific binding.  In the native HNE sample, an additional band below 15 kDa is also labeled on 
the Western blot (Figure 3.5b) and corresponds to an autolytic fragment that is also seen in 
commercial preparations from whole blood (http://www.abcam.com/Neutrophil-Elastase-
protein-Active-ab91099.html).   
Attempts were made (not shown) to further purify the enzymes by ion exchange 
chromatography as well as affinity chromatography on columns with immobilized inhibitors 
basic pancreatic trypsin inhibitor (BPTI, Trasylol®) and secretory leukocyte proteinase inhibitor 
(SLPI); however, these pursuits met with limited success.  In the case of BPTI, a small amount of 
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activated rHNE was recovered but most activity did not adsorb and the results were not 
reproducible.  HNE affinity for the SLPI affinity column was very strong and resulted in 
complete adsorption of rHNE activity.  This rHNE activity was never recovered successfully, 
despite the use of various denaturants and chaotropic agents.  Of these, 8 M urea released some 
measurable activity from the column yet only about 20% of the original activity could be 
accounted for; furthermore, 8 M urea did not reduce the activity of HNE.  The further 
purification of rhCatG has also been unsuccessful thus far. 
 
Partial Purification and Activation: rHNE in K. lactis 
 Despite poor production with the K. lactis expression platform, CytB5-rHNE was 
partially purified from K. lactis fermentation medium, but without the use of buffer exchange or 
ultrafiltration.  Recombinant protein was detectable in IMAC elution fractions by the presence of 
410 nm peaks in the absorbance spectra, as in Figure 3.4a; however, absorbance at 280 nm was 
obscured by excess imidazole.  The intensity of 410 nm absorbance was very low (<0.06 units) 
and indicative of poor recovery.  Samples activated with varying amounts of EP (volumes listed, 
concentration unknown) revealed the activation of rHNE as a function of time and the amount of 
EP used (Figure 3.7).  Based on the final maximum activity (Figure 3.7), only 100 ng of active 
rHNE was recovered in the most active fraction and the total recovery was less than 1 µg. 
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Figure 3.7:  Activation of CytB5-rHNE Partially Purified by IMAC from K. lactis 
Fermentation Medium.  Identical 50 µL samples were treated with the indicated volumes of an 
EP sample (concentration unknown) in a total reaction volume of 100 µL.  After 4 hours 
(yellow) and 24 hours (blue), samples were measured for activity with chromogenic MeO-Suc-
AAPV-pNA.  The results show that IMAC purified CytB5-rHNE from K. lactis is activated by 
EP and that increasing amounts of EP reduced the amount of time needed for the fusion protein 
to become fully active.  Based on the maximum activity (~ 0.5 mA410/min), this 2 mL fraction 
contains only about 100 ng of active rHNE (150 ng of activable CytB5-rHNE). 
 
 Extremely low levels of expression and inefficient IMAC recovery hindered the 
expression of rHNE and rhCatG in K. lactis.  Work with this yeast occurred prior to the more 
successful efforts with P. pastoris; furthermore, limited experience with yeast fermentation 
during the work with K. lactis may have contributed to the poor results of this expression 
platform.  The low level expression and purification of CytB5-rHNE from K. lactis, as well as 
the accompanying 410 nm absorbance properties of the protein, encouraged the further pursuit of 
this fusion construct design; however, the decision was made to change to the P. pastoris 
platform due to the volume of research available, as well as the prior familiarity of the 
investigators, for this system. 
 
93 
 
The Utility of Cytochrome B5 Fusion Domains in Recombinant Protein Expression 
The heme-bound CytB5 fusion protein expression in P. pastoris has several implications 
that extend well beyond the specific expression of these two recombinant serine proteases.  
First, the red coloration of the cells, concentrated media, adsorbed samples on resins, and 
eluted fractions, significantly improves the processes of fermentation and purification through 
the use of visual confirmation and characteristic absorbance spectrum patterns to follow protein 
location and concentration.  It is hypothetically possible, although as yet experimentally 
unconfirmed, that, if used in conjunction with the constitutively active GAP transcriptional 
promoter, transformant cells might even express sufficient CytB5-based coloration on agar 
selection plates to facilitate the identification of “super-producing” clones through the use of 
simple visual observation during the transformant selection process. 
Second, the ratio of the intensities of 410 nm and 280 nm absorbance peaks, A410/A280, 
can be used to evaluate the relative purity and concentration of a sample.  In the case of the NSPs 
expressed here, the A410 reflected not only full length protein but also heme-binding, partially 
translated products and this is a consequence of the use of an N-terminal 6xHis tag.  With the use 
of a C-terminal tag or other purification strategy designed to recover only full-length 
recombinant proteins, the A410 would more accurately reflect the concentration.  The molar 
extinction coefficient of heme-bound CytB5 at 413 nm absorbance is 114,000 M-1 cm-1 for the 
oxidized form and 185,000 M-1 cm-1 for the reduced form
71
.  It is, however, important to note 
that only a portion of the CytB5 fusion protein is in the heme-bound form
71
, which is necessary 
for the 410 nm absorbance; consequently, the A410 cannot be used to directly quantify the total 
concentration of fusion protein, only the heme-bound fraction.   
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The ratio of A410/A280 does correlate with the relative level of purity of the sample.  In 
the case of CytB5-rHNE and CytB5-rhCatG, the most active fraction of rHNE (Figure 3.4a, 
Fraction 6) has an A410/A280 ratio = 0.68 whereas the most active fraction of rhCatG (Figure 
3.4b, Fraction 36) has an A410/A280 ratio = 0.13.  This means that a larger percentage of the 
protein in the rHNE fraction is heme-bound fusion protein than the percentage of rhCatG in its 
equivalent fraction. 
Third, the accumulation of dark red color in cells and culture media post-induction 
relative to uninduced and untransformed cultures confirms that the two yeast species 
manufacture hemin endogenously and that the induced overexpression of CytB5 fusion 
constructs creates a “heme-sink” in the yeasts that is similar to results shown previously in E. 
coli
76
.  Centrifuged cell pellets from harvested P. pastoris fermentation cultures retained a dark 
pink color that, even after extensive rinsing with buffers of high ionic strength, was only 
extractable in a supernatant upon yeast cell lysis by French pressure cell disruption, sonication, 
or manual glass-bead disruption methods; however, treatment of these cell extracts with EP did 
not result in active rHNE or active rhCatG. 
This suggests that the majority of CytB5-rHNE and CytB5-rhCatG proteins being 
produced were retained by the cells and either misfolded or degraded.  Recently, it has been 
shown that P. pastoris expressing recombinant proteins under control of the methanol inducible 
AOX1 promoter, but not the constitutively active GAP promoter, also exhibited secretory 
limitations that resulted in accumulation of product in the ER and initiation of the ERAD 
pathway
77
.  Expression of the CytB5 NSP fusion proteins may prove more successful with the 
use of the constitutive GAP promoter.  If these proteins were more efficiently secreted, the 
locations and intensities of the CytB5-based 410 nm absorbance peaks might reflect this. 
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Conclusions 
 Further efforts are warranted in the recombinant expression of HNE and CatG based on 
their successful secretion and partial purification from P. pastoris.  Strains of this yeast have 
recently been made available that express proteins with human glycosylation patterns (Pichia 
GlycoSwitch®; http://www.rctech.com/licensing/gxt-pichia-glycoswitch.php); consequently, 
variants of rHNE and rhCatG should be attempted in which the native glycosylation sites have 
not been disrupted.  It is likely that the use of the constitutively active GAP transcriptional 
promoter instead of AOX1 would improve the secretory capacity of the cells
77
 and this is 
especially important in the case of CatG due to its low levels of expression.  The procedures and 
materials for purifying active rHNE and rhCatG must be revisited and optimized to improve both 
the yield and purity of the recovered products. 
 The results of CytB5 fusion protein expression are encouraging with regard to the use of 
CytB5 for the detection of protein production and purification using yeast expression platforms, 
as has previously been demonstrated for E. coli
71,72
,  and this method is worthy of further 
application.  The expression of rHNE and rhCatG would have been much more difficult without 
observation of the 410 nm peak in the absorbance spectra because these enzymes require 
enzymatic activation prior to detection and quantification based on activity.  Absorbance maxima 
at 280 nm are sufficient to follow total protein recovery during the purification process; however, 
confirmation of protein location by the presence of a red color enabled the visual verification of 
protein expression and optimization of protein purification. 
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Materials and Methods 
Molecular Cloning 
 The NCBI database was used as a source for the native amino acid sequences of HNE 
(NCBI Ref. Seq. NP_001963.1) and CatG (NCBI Ref. Seq. NP_001902.1).  The amino acid 
sequence of the soluble heme-binding domain of R. norvegicus CytB5 (from NCBI Ref. Seq. 
NP_071581.1) was identical to that previously used for recombinant expression in E. coli
71
.  All 
amino acid and gene sequences were analyzed and modified using the software Geneious® 6.1.4 
(Biomatters, http://www.geneious.com).  Custom genes were codon-optimized for expression in 
P. pastoris and K. lactis and synthesized by GenScript, who provided the genes in pUC57 
plasmids for subcloning.  The CytB5 gene was flanked by 5’ XhoI and 3’ KpnI restriction sites 
whereas both rHNE and rhCatG included 5' KpnI and 3’ NotI sites.   
Standard techniques were used throughout the molecular cloning process.  Briefly, 
plasmids were treated with appropriate restriction enzymes (Thermo Scientific, Fermentas 
FastDigest®) and digestion fragments were recovered from agarose gels using the Zymoclean™ 
gel DNA recovery kit (Zymo Research).  The recovered inserts were ligated into the multiple 
cloning sites (MCSs) of the target plasmids using Quick-Stick Ligase (Bioline) and transformed 
into Z-Competent™ chemically competent DH5α E. coli (Zymo Research).  Plasmid assembly 
occurred in two stages.  First, the CytB5 gene was inserted separately into both pPICzα A and 
pKLAC1 expression plasmids using XhoI and KpnI restriction sites to position the inserted 
sequence in the correct reading frame at the 3’ end of the sequence encoding α-mating factor and 
the two plasmids were designated as pPICzα-CytB5 and pKLAC1-CytB5.  Second, the rHNE 
and rhCatG genes were inserted similarly into the MCSs of pPICzα-CytB5 and pKLAC1-CytB5 
with the restriction sites KpnI and NotI.  The sizes of all plasmid inserts were verified by PCR to 
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amplify the MCS contents using primers provided with the yeast expression kits, GoTAQ® All-
In-One Master Mix DNA Polymerase (Promega) and its protocols. 
 
Transformation of P. pastoris 
 The P. pastoris transformation protocol was adapted from instructions for the 
EastSelect™ Pichia Expression Kit (Life Technologies).  The plasmids, designated pPICzα-
CytB5-rHNE and pPICzα-CytB5-rhCatG, were treated with the restriction enzyme BstXI to 
generate linearized insertion cassettes for electroporation.  These cassettes were recovered with a 
DNA cleanup kit (Zymo) and further concentrated by ethanol precipitation.  X-33 P. pastoris 
cultures were prepared for and transformed by electroporation as prescribed by Life 
Technologies, using a cuvette with a 2 mm gap and a BTX ECM 600 electroporation system 
with settings at 1.5 kV and 186 Ω to result in a 7.5 msec pulse length.  Transformants were 
selected for resistance by growth at 30 °C on YPDS agar plates with ampicillin and Zeocin™ 
(100 µg/mL, each) and positive colonies were re-plated to fresh YPD agar plates, also containing 
ampicillin and Zeocin™, and numbered for further screening. 
 
Transformation of K. lactis 
 The chemical transformation of K. lactis used reagents and followed instructions 
provided with the K. lactis Protein Expression Kit (New England Biolabs, NEB).  The plasmids, 
pKLAC1-CytB5-rHNE and pKLAC1-CytB5-rhCatG, were both linearized with the BstXI 
restriction enzyme and recovered with a DNA clean up kit (Zymo).  Chemically competent 
GG799 K. lactis were thawed, treated with linearized DNA and a transformation reagent, and 
subjected to treatment as per instructions.  Transformed cells expressing the enzyme acetamidase 
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were selected for growth at 30 °C on nitrogen-free yeast carbon base (YCB) agar plates 
containing 5 mM acetamide.  Positive colonies were re-plated to YPD agar plates and numbered 
for further screening. 
 
Expression Screening 
 Culture Conditions.  Numbered clones were grown under sterile conditions as either 2 
mL liquid cultures in 12-well plates or 10 mL cultures in 50 ml conical tubes, depending on the 
number of transformants available.  P. pastoris were grown in synthetic minimal medium 
(SMM) comprised of 10 g/L monosodium glutamate (MSG), 2.5 mg/L (NH4)2(SO4), 1.34% yeast 
nitrogen base, >4 x 10
-5
% biotin, and 100 mm potassium phosphate at pH = 5.0 and containing 
100 µg/mL of both ampicillin and Zeocin® (Life Technologies); furthermore, they were fed 1% 
methanol every 24 hours and grown with orbital shaking at 28.5 °C for 4 days prior to harvest.  
K. lactis were grown in SMM at pH = 7.0 containing 2% casamino acids and 100 µg/mL of 
ampicillin.  K. lactis were fed 1% galactose every 24 hours and grown with orbital shaking at 
28.5 °C for 4 days prior to harvest.  Culture supernatants were clarified by centrifugation and 
retained, along with the separate cell pellet, for further analyses. 
 Enzyme Activation.  Supernatants from screening cultures were adjusted to pH = 8.0 by 
titration with 1 M Tris, pH = 9.0 and centrifuged to remove insoluble material.  Samples were 
treated with EP overnight at 37 °C prior to activity testing. 
 Activity Assays.  All reported activity assays for HNE and CatG activity, regardless of 
source, purity, or stage of analysis, follow this protocol. EP-treated samples were tested for the 
enzymatic cleavage of chromogenic, synthetic peptide substrates.  Methoxysuccinyl-AAPV-
para-nitroanilide (MeO-Suc-AAPV-pNA; EMD Millipore Cat#454454) and the similar 
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thiobenzyl ester substrate Suc-AAPV-SBzl (LifeTein custom synthesis) were used to detect HNE 
activity; similarly, CatG activity was detected with Suc-AAPF-pNA(Sigma  #S-7388) and Suc-
AAPF-SBzl (LifeTein custom synthesis).  Assays were conducted in 100 µL reaction volumes in 
96-well microtiter plates and monitored over the course of 10 minutes for the accumulation of 
410 nm absorbance indicating substrate cleavage.  Each reaction was composed initially of 5 to 
25 µL of activated sample with sufficient assay buffer containing 100 mM HEPES, 1 M NaCl, 
10 % glycerol, 0.01 % Trition X-100, and 0.01 % NaN3 at pH = 8.0 to bring the total volume to 
50 µL.  Immediately prior to initiating the absorbance assay, 50 µL of substrate buffer made 
from the assay buffer with 300 µM of the appropriate substrate were added to the reaction 
mixture.  Assays using the thiobenzyl ester substrates also contained 100 mM DTNB. 
 PCR Testing for Multicopy Transformants.  Genomic DNA (gDNA) samples were 
recovered from cell pellets by phenol/chloroform extraction and ethanol precipitation using 
standard procedures
78-81
.  The integrity of all gDNA samples was confirmed by gel 
electrophoresis using the FlashGel cartridge system (Lonza) per its instructions.  PCR for single- 
and multi- copy integrations were conducted using the procedure and integration primers 
provided with the EasySelect™ Pichia Expression Kit (Life Technologies).  PCR screening of K. 
lactis used the procedure and primers provided with the K. lactis Protein Expression Kit (NEB).  
All PCR used GoTAQ® All-In-One Master Mix DNA Polymerase (Promega) and its protocols. 
 
Fermentation and Media Processing 
 All fermentations were conducted in a BioFlo 110 bioreactor (New Brunswick), 
following its user’s manual, with a dissolved oxygen sensor (Mettler-Toledo) and a pH probe to 
monitor culture conditions.  Cultures were grown following the guidelines of the Pichia 
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Fermentation Process Guidelines by Life Technologies and modifying feed and media 
formulations as needed.  Several growth media were tried for P. pastoris and K. lactis based on 
the formulae for basic salts medium (BSM) recommended by the Life Technologies guidelines 
and FM22
82
 and using their respective trace element supplements, PTM1 and PTM4.  The most 
successful medium formulation was found to be a variation of BSM supplemented with PTM4 to 
reduce the formation of insoluble salts.  This BSM variant included the addition of 10 g/L MSG 
and a supplementary vitamins mix that was made as a 100x concentrate containing 0.1 g/L L-
His-HCl, 0.2 g/L DL-Met, 0.2 g/L DL-Trp, 0.0002 g/L biotin, 0.0002 g/L folic acid, 0.2 g/L 
inositol, 0.04 g/L niacin, 0.02 g/L p-aminobenzoic acid, 0.04 g/L pyridoxine HCl, 0.02 g/L 
riboflavin, 0.04 g/L thiamine HCl, 0.04 g/L calcium pantothenate, 10 g/L CaCl2.   
Upon harvest, fermentation media supernatants were clarified by centrifugation followed 
by filtration through glass fiber pre-filters (Millipore Cat#AP2004200) and 0.45 µm filters (Pall 
P/N 60173).  Clarified P. pastoris broth volumes were reduced by ultrafiltration with 10 kDa 
molecular weight cut-off (MWCO) tangential flow filtration cartridges (Sartorius Vivaflow50 
P/N VF05P0).  During ultrafiltration, the media were flushed extensively with IMAC binding 
buffer containing 25 mM sodium phosphate and 300 mM NaCl at pH = 8.0.  K. lactis 
fermentation supernatants were not subject to ultrafiltration. 
 
Immobilized Metal Affinity Chromatography 
 IMAC used either His-Bind® Resin (EMD Millipore) or Profinity™ IMAC Resin (Bio-
Rad).  All stripping, equilibration, loading, washing, and elution buffers contained 25 mM 
sodium phosphate and 300 mM NaCl at pH = 8.0.  The metal ion stripping buffer contained 100 
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mM EDTA; the equilibration and loading buffers contained no additional components; the 
washing buffer contained 5 mM imidazole; the elution buffer contained 20 mM imidazole. 
 
SDS-PAGE and Western Blotting 
 NuPAGE® Bis-Tris polyacrylamide gels (Life Technologies) were run using MOPS-
SDS running buffer and stained with Coomassie blue stain (SimplyBlue™; Life Technologies).  
For Western blotting, gels were run as above and blotted to PVDF by semi-dry transfer.  
Membranes were blocked with 1% BSA in TBST.  The primary antibody was polyclonal rabbit 
anti-HNE (Athens Research) and the secondary antibody was polyclonal goat anti-rabbit HRP-
conjugate (Pierce). 
 
Spectrophotometry 
 All protein absorbance values and spectra were read on a Biotek PowerWave™ XS2 
plate reader using Corning Half Area 96 well plates P/N 3679.  For DNA samples, 
concentrations were determined by measuring absorbance in a NanoVue™ spectrophotometer 
(GE). 
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Abstract 
 C-reactive protein (CRP) is an acute phase protein that binds phosphocholine (PCh) and 
the complement protein C1q.  CRP in known to bind oxidized LDL (oxLDL) under acidic 
conditions and the E42Q amino acid substitution improves oxLDL binding at physiological pH.  
Recombinant wild-type human CRP (rCRP) and the rCRP E42Q substitution variant were 
expressed in the yeast Pichia pastoris under methanol induction, yielding correctly folded and 
functional pentameric proteins in the culture media.  For rCRP, 3.7 mg/L were expressed when 
grown in synthetic minimal medium in baffled shaker flasks while the rCRP E42Q variant 
expressed 1.7 mg/L and these proteins were purified by PCh affinity chromatography.  Both 
proteins were shown to bind to immobilized PCh like native human CRP (hCRP); however, 
rCRP was expressed in two forms, one with the correct monomeric molecular mass of ~25 kDa 
and a second, slightly larger monomeric form, as shown by SDS-PAGE and Western blot with a 
CRP-specific antibody.  A later SDS-PAGE only showed a single band for rCRP purified by PCh 
affinity.  The two forms could not be separated by PCh affinity chromatography, ion-exchange 
chromatography, or gel-filtration chromatography.  The source of the extra mass has not been 
determined. 
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Introduction 
 C-reactive protein (CRP) expression by hepatocytes increases rapidly early in the acute 
phase response of innate immunity, with plasma levels increasing as much as 1000-fold in 
response to acute inflammatory stimuli
1
.  CRP was discovered in 1930
2
 for its ability to 
precipitate C-lipopolysaccharide present on the cell wall of Streptococcus pneumonia.  Later, 
phosphocholine (PCh) was identified as the component of C-lipopolysaccharide that serves as 
the ligand for CRP
3
.  PCh-associated CRP binds complement component C1q and allows CRP to 
activate the classical complement activation cascade, although only C1-C4 are activated, without 
activation of the later complement components C5-C9
1,4
.  CRP has also been shown to have 
other potential binding partners, including chromatin, fibronectin, histones, laminin, 
phosphoethanolamine, ribonuclear proteins, oxidized LDL (oxLDL), and the oxLDL receptor 
LOX-1
5-9
. 
 CRP is a member of the pentraxin family of acute phase pattern recognition receptors, 
characterized by a homopentameric functional form.  Identical monomers form a ring primarily 
via electrostatic surface interactions between subunits.  One side of the ring, the recognition face, 
contains five calcium-dependent PCh binding sites, one on each subunit
4
.  The other face, the 
effector face, binds the globular head of complement component C1q, which spans the central 
pore of CRP
10; furthermore, the binding of CRP with immunoglobulin Fcγ receptors11,12 is also 
thought to occur on the effector face
1
.   
   Patients with chronically elevated CRP levels have greater risk of diabetes
13,14
, 
atherosclerosis
15-20
, and cardiovascular disease
21-24
.  CRP is frequently used as a clinical marker 
of inflammation and cardiovascular disease, as recommended by the American Heart Association 
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and the Centers for Disease Control and Prevention
25-27
.  CRP displays both pro-inflammatory 
and anti-inflammatory
8,11,28-30
 activities whose net in vivo effects may depend on the context. 
 CRP has been shown to bind oxLDL under acidic conditions
20,31,32
 and the single residue 
variant CRP E42Q also binds oxLDL at physiological pH
9
, likely by relaxing the interface 
between the CRP subunits to improve the flexibility of the pentamer.  Wild type and substitution 
variants of CRP have been expressed as recombinant proteins in several expression systems 
including E. coli, Leishmania tarentolae, Trichoplusia ni, and the yeast Pichia pastoris
33-36
.  
CRP recently expressed in P. pastoris was found to contain the additional amino acid sequence 
EAEA at the N-terminus
36
 because these amino acids were used to separate the kexin cleavage 
site (KR) from the CRP N-terminus.  These extra amino acids are not always completely 
removed by the Ste13 dipeptidyl peptidase in P. pastoris following cleavage by kexin.  While the 
additional N-terminal amino acids did not seem to affect its function, the expression of wild-type 
CRP, without added amino acids, in P. pastoris would provide a robust source of recombinant 
protein that is structurally and functionally identical to the native human pentamer and an easier 
method for producing variants. 
 For further study regarding the binding of CRP to oxLDL, both recombinant wild type 
CRP (rCRP) and the single amino acid variant rCRP E42Q were expressed as secreted proteins 
in P. pastoris, quantified by ELISA, and tested for PCh affinity.  Both proteins formed 
pentamers, as evinced by the ability to bind PCh like the native human CRP (hCRP) pentamer.  
Wild type rCRP was further analyzed by SDS-PAGE and Western blot and it was found in two 
monomeric forms of distinct molecular mass.  Despite further purification efforts with anion 
exchange chromatography and gel filtration, the two forms of wild type rCRP could not be 
separated and this indicates that these two rCRP monomer types associated randomly into 
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pentamers.  The problem could be unique to the transformant clone that was selected for 
expression or due to the culture conditions during expression; however, further studies are 
required to resolve this issue. 
 
Results 
Protein Engineering and Molecular Cloning 
  Amino acid sequences for mature hCRP (NCBI Ref. Seq. NP_000558.2) and the CRP 
E42Q single residue substitution variant were used, without further modification, to generate 
synthetic cDNAs codon optimized for expression in the yeast P. pastoris.  The yeast were 
transformed with pPICzα A plasmids under transcriptional regulation of the methanol-inducible 
AOX1 promoter and directed for secretion by the α-mating factor secretion signal sequence that 
is removed by kexin during secretion.  The kexin cleavage sequence, KR, is adjacent to the N-
terminus of each CRP sequence, with no intervening residues (Figure 4.1) 
 
 
Figure 4.1: Primary Structure of rCRP Construct with α-Mating Factor.  The amino acid 
sequence for rCRP (Black) with the α-mating factor secretion signal (Red) connected to the N-
terminus of mature CRP by the kexin cleavage sequence KR~ (Blue), where “~” represents the 
site of kexin mediated proteolysis.  The substitution of Glu 42 (Green) with Gln 42 is the only 
difference in the sequence of rCRP E42Q and these proteins contain no other modifications.  In 
the genes for both constructs, two stop codons (not shown) immediately follow the codon for the 
C-terminal Pro 206. 
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 The codon-optimized sequences for both constructs were cloned into the pPICzα A 
expression plasmid for P. pastoris, under control of the repressible, methanol-inducible 
transcriptional promoter AOX1.  These plasmids were used to transform the X-33 strain of P. 
pastoris and positive transformants were selected by Zeocin® resistance for further screening. 
 
Transformant Screening  
Transformant clones of both protein variants were screened for best production using 2 
mL cultures grown in synthetic minimal medium (SMM) in 12-well microtiter plates.  These 
cultures were grown for four days with methanol induction prior to harvest.  Upon harvest by 
centrifugation, the wet cell pellet weights (WCW, g/L) were measured for all cultures.  CRP 
production levels in culture supernatants were quantified (µg/L) by sandwich ELISA with a 
polyclonal rabbit anti-human CRP IgG as the capture antibody, the mouse monoclonal anti-CRP 
antibody HD2.4 for detection, and an HRP-conjugated goat anti-mouse secondary antibody for 
chemiluminescence.  The ELISA results were normalized to the WCW measurements to 
determine ratios of production/cell mass, in units of µg protein/g WCW.  These values were 
analyzed to find the cultures expressing the most protein/cell mass.  Of 47 clones screened for 
each construct, four were selected for further analyses. 
For the narrower pool of eight transformants (two sets of four clones), 10 mL cultures 
were grown, inoculated to equal starting optical densities, OD600 = 1.0, in 50 mL conical tubes 
in SMM with 1% methanol and fed 1% methanol each day for four days.  These cultures were 
analyzed again, as above, to isolate the most productive clone for each product.  
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Protein Expression 
 The best producing clones were scaled up to 300 mL volumes of media in baffled flasks.  
Various growth media based on recipes for BMMY and SMM were employed in efforts to 
improve expression and secretion.  The formulae experimented with these parameters: 
temperature, pH, Ca
2+
 content, ionic strength, phosphate source (potassium orthophosphate or 
sodium hexametaphosphate), culture volume (up to a 5 L scale in bioreactor fermentations), 
induction phase length, methanol concentration, and induction co-feeding with glycerol or 
sorbitol.  Both BMMY-based and SMM-based media performed similarly; however, SMM 
media were preferred for the improved regulation of culture conditions that they afford.  The best 
expression results were 3.7 mg/L of rCRP and 1.7 mg/L of rCRP E42Q, both achieved in normal 
SMM at pH = 5.0 and buffered with potassium phosphate.  These cultures were fed 1% methanol 
each day for four days in 1 L baffled shaking flasks no more than 1/3 full with broth at 28.5 °C.  
Glycerol and sorbitol co-feed attempts did not improve yields of either CRP construct; 
furthermore, production was markedly reduced by glycerol (a known repressor of the AOX1 
promoter).   
 
PCh Binding Assays 
 Expression media for both recombinant variants were tested for binding to immobilized 
PCh.  These assays were performed similar to the sandwich ELISA; however, the polyclonal 
rabbit anti-CRP antibody was replaced by immobilized PCh-BSA for CRP capture.  Serial 
dilutions of rCRP culture growth media displayed binding to PCh-BSA that was dependent on 
Ca
2+ 
and inhibited with EDTA (Figure 4.2a).  PCh-BSA affinity was also dependent on either the 
rCRP or rCRP E42Q concentration with results matching the behavior of the native human 
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pentamer across the same concentration range (Figure 4.2b).  These assays show that both 
recombinant variants were secreted as stable pentamers because monomeric CRP has a 
significantly lower affinity for PCh-BSA
32
.  Both variants could also be recovered from culture 
media by PCh-agarose affinity chromatography; however, problems emerged during the 
purification process.  Low levels of protein expression and the heavy formation of insoluble 
phosphate salts in culture supernatants during purification led to reformulation of the growth 
conditions and media.  The best results were achieved with SMM at pH = 6 with 100 mM 
potassium phosphate and fed 1% methanol daily for four days.  At lower pH, CRP is more likely 
to stick to other things and many previous cultures had been grown at pH = 5.  Increasing the pH 
caused the formation of insoluble phosphates; consequently, the clarified culture supernatants 
were adjusted to pH = 8 followed by centrifugation and filtration to precipitate and remove as 
much insoluble phosphate as possible.   The E42Q variant was not further characterized and all 
subsequent work focused on the production and purification of wild type rCRP, as shown below. 
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Figure 4.2:  PCh Binding Assays.  For PCh binding assays, microtiter plate wells with 
immobilized PCh-BSA were used to capture CRP from culture medium.  Adsorbed CRP was 
then detected with the monoclonal mouse anti-CRP antibody HD2.4 and an HRP-conjugated 
goat anti-mouse secondary antibody.  (A) Serial dilutions of culture medium showed binding of 
rCRP to PCh-BSA in the presence of Ca
2+
 and the sequestration of Ca
2+
 with EDTA significantly 
reduced this affinity, consistent with the known behavior of native hCRP.  (B)  The binding of 
rCRP and rCRP E42Q to PCh occurred in a concentration-dependent manner identical to the 
behavior of native hCRP.  This confirms that rCRP and rCRP E42Q are expressed and secreted 
as functional pentamers because the PCh binding affinity of monomeric CRP is significantly 
weaker
32
.  
 
Initial Purification and SDS-PAGE   
Wild type rCRP was recovered from culture medium by immobilized PCh affinity 
chromatography.  Following this single-step purification, samples were analyzed by SDS-PAGE 
(4% - 20%) under reducing conditions (Figure 4.3a).  Although hCRP migrated as a single band 
at the correct molecular weight, rCRP migrated as two bands (Figure 4.3a).  The more prominent 
band, of lower molecular mass, migrated at the same molecular weight as native protein; 
however, the less prominent band has an apparent molecular mass of ~1 kDa greater than hCRP 
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(Figure 4.3a).  A later, separate SDS-PAGE (12%) under reducing conditions (Figure 4.3b) did 
not reveal the contaminant band in rCRP, although this may be due to overloading. 
 
                                                     
Figure 4.3:  SDS-PAGE of PCh-Affinity Purified rCRP.  (A) A 4% - 20% SDS-PAGE, under 
reducing conditions, compares hCRP with rCRP upon single-step purification by affinity for 
PCh.  The rCRP migrates as two bands of distinct molecular mass, unlike the expected single 
band of ~25 kDa, as shown for hCRP.  The band of lower mass migrates like hCRP; however, a 
second band of higher mass also appears approximately 1 kDa above.  The band of larger mass 
represents approximately 20% of the total protein in the sample, estimated by densitometry.  (B)  
In a separate reducing gel (12% SDS-PAGE), rCRP and hCRP both migrate at ~25 kDa, 
although the second band appearing in (A) may be obscured in the broader band in (B). 
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Further Purification 
 Because a second band was initially found to co-purify with rCRP based on PCh affinity, 
further attempts were made to separate these two proteins by a three step process.  First, rCRP 
was purified by PCh (Figure 4.4a), as above.  Second, PCh-purified rCRP was further purified by 
anion exchange (Figure 4.4b).  Third, the dual-purified sample was separated by gel filtration 
(Figure 4.4c).  Sample recovery data chronicles each stage of purification (Table 4.1). 
 
 
Figure 4.4:  Three Step Purification of rCRP.  (A) An elution profile for purification of rCRP 
by PCh affinity chromatography.  Fraction volumes were 500 µL and fractions 13 – 28 were 
pooled (5.5 mL) for subsequent steps.  (B)  This pooled sample was further purified by anion 
exchange chromatography, which eluted as a single peak and focused the protein into a smaller 
elution volume (2 mL pooled).  (C)  The anion exchange elution pool was separated by gel 
filtration and eluted as a single major peak. 
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  At each step of the purification, samples were collected for analysis by SDS-PAGE, with 
each sample loaded in 1 µg and 5 µg quantities (Figure 4.5).  PCh-purified rCRP, both with and 
without EDTA, migrated with the same pattern as before; furthermore, the two bands failed to 
separate at any stage of purification (Figure 4.5). 
 
 
Figure 4.5:  SDS-PAGE of Three Step rCRP Purification.  Samples from each step of the 
three-stage purification of rCRP are shown in comparison to hCRP.  In each step, the two bands 
fail to separate and the purity was never improved beyond the single-step PCh affinity 
purification.  The band of larger mass represents approximately 20% of the total protein in the 
sample. 
 
Total rCRP 
(mg)
rCRP Concentration 
(µg/mL)
Yield (% of Input)
SMM (PCh Input) 2.14 3.2
PCh Recovery 1 200 46.7
Anion Exchange Input 0.885 200
Anion Exchange Recovery 0.573 287 64.7
Gel Filtration Input 0.48 1370
Gel Filtration Recovery 0.147 70 30.6
Table 4.1:  Three Step Purification of rCRP
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 Purified hCRP and rCRP were analyzed by Western blotting (Figure 4.6).  Both were 
labeled by the polyclonal rabbit anti-CRP primary antibody and heavy sample loading shows 
some CRP degradation products in both sample types (Figure 4.6).  Of particular importance, 
both bands of the purified rCRP are labeled by the antibodies, indicating that the band with       
~1 kDa more mass is likely an modified form of the protein (Figure 4.6).  
 
 
Figure 4.6:  Western Blot of hCRP and rCRP.  Purified hCRP and rCRP samples of 75 ng, 
150 ng, and 300 ng were loaded, as indicated.  The PVDF membrane was probed with the 
polyclonal rabbit anti-CRP primary antibody and an HRP-conjugated donkey anti-rabbit 
secondary antibody.  For both hCRP and rCRP, some degradation products can be seen.  Both of 
the bands that appear on the SDS-PAGE for the purified rCRP samples are labeled by the anti-
CRP antibodies on the Western blot, indicating that the band of larger molecular mass may be a 
modified version of the correctly expressed protein. 
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Discussion 
 Both recombinant CRP variants were present as functional pentamers in the culture 
supernatant.  This was confirmed by the binding of the proteins to immobilized PCh-BSA in a 
manner dependent on the concentrations of Ca
2+
 and CRP (Figure 4.2).  The successful 
expression of functional rCRP and rCRP E42Q in P. pastoris provides a useful source for 
producing these proteins efficiently in large quantities.  This expression platform may provide 
further use for the production of other CRP variants as well.  The presence of a second band of 
protein that co-purified with rCRP provides a puzzle that has not yet been solved.  Because later 
SDS-PAGE of samples purified by PCh (Figure 4.3b) did not reveal the presence of this band, it 
may be due to an unknown experimental effect or changes in growth conditions during protein 
production.  Examination of other transformed clones may reveal that the second band is 
anomalous exclusively to the selected clone.   
If the second band truly does co-purify with rCRP and is not an artifact, then further 
analyses are required to determine the source of this modification.  It is possible that a portion of 
the protein was post-translationally modified in some unforeseen manner; however, no 
glycosylation sites are present.  An SDS-PAGE (not shown) was treated with a stain specific for 
phosphorylated proteins and found that both hCRP and rCRP stained to the same extent.  Mass 
spectrometry may illuminate this issue. 
Although much exploration of culture media and growth conditions failed to improve the 
expression of these proteins beyond 4 mg/L, significant experience has been gained during this 
process regarding the production of recombinant proteins in the yeast P. pastoris.  With further 
attempts, it is anticipated that bioreactor-based yeast fermentation may yield improved results 
relative to those previously seen for the expression of CRP.  Finally, although the synthetic genes 
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used for rCRP and rCRP E42Q were produced by two different companies using different 
optimization algorithms the expression levels did not differ significantly. 
 
Materials and Methods 
Molecular Cloning and Yeast Transformation 
 The amino acid sequence for hCRP was taken from the NCBI database (NCBI Ref. Seq. 
NP_000558.2).  Codon-optimized gene sequences were optimized and synthesized by DNA2.0 
(rCRP E42Q) and by GenScript (rCRP) and provided with 5’ XhoI and 3’ NotI in the pUC57 
subcloning vector.  The coding sequence was cloned into the pPICzα A P. pastoris expression 
plasmid (Life Technologies) using standard molecular cloning techniques, as described in the 
EasySelect ™ Pichia Expression Kit (Life Technologies).  The restriction enzymes were 
FastDigest® enzymes (Thermo Scientific).  Digestion fragments were separated by agarose gel 
electrophoresis and gel extraction (Zymo).  Protein-coding inserts were ligated into pPICzα A 
with Quick-Stick Ligase (Bioline) and the assembled plasmids were propagated in Z-
Competent™ DH5α E. coli (Zymo) and transformed E. coli were screened for Zeocin™ 
resistance. 
 X-33 P. pastoris were transformed with linearized expression plasmids by 
electroporation using the protocol in the EasySelect™ Pichia Expression Kit (Life 
Technologies).  Electroporation was conducted using cuvettes with a 2 mm gap in a BTX ECM 
600 electroporation system set at 1.5 kV and 186 Ω with an approximate pulse length of           
7.5 msec.  Transformants were grown at 30 °C on YPDS agar plates containing 100 µg/mL of 
Zeocin™ for transformant selection and 100 µg/mL of ampicillin to prevent bacterial 
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contamination.  After three days, individual colonies were plated to fresh YPD agar plates (with 
the same antibiotics) and numbered. 
 
Transformant Screening 
 Numbered clones were grown in 2 mL cultures in 12-well plates in synthetic minimal 
medium (SMM) comprised of 10 g/L monosodium glutamate (MSG), 2.5 mg/L (NH4)2(SO4), 
1.34% yeast nitrogen base, >4 x 10
-5
% biotin, and 100 mm potassium phosphate at pH = 5.0 and 
containing 100 µg/mL of both ampicillin and Zeocin® (Life Technologies).  The medium was 
supplemented with 1% methanol and an additional 0.5% methanol was added each day for four 
days.  After four days, the cultures were harvested and the wet cell pellet weights (WCW) were 
determined.  Culture supernatants were clarified by centrifugation and screened by ELISA (see 
below) for the presence of CRP.  The ELISA results for CRP concentration (µg/mL) were 
normalized by dividing by the WCW (mg/mL) to determine production efficiency (µg 
protein/mg WCW).  The four most productive clones of rCRP and of rCRP E42Q (eight total 
clones) were identified and further screened for production in larger volumes. 
 In the second phase of colony screening, the most productive clones were all growth from 
the same starting density (OD600 = 1.0) in SMM containing 1% methanol and fed 1% methanol 
every day for four days.  These cultures were grown in 10 ml volumes in 50 ml sterile conical 
tubes with shaking at 30 °C.  These clones were analyzed as described above for the 2 mL 
cultures. 
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ELISA 
 Sandwich-type ELISA analyses quantified recombinant protein samples relative to a 
standard curve following the protocol previously published for quantification of CRP
37
.  
Microtiter plate wells were treated with 100 µL of polyclonal rabbit anti-human CRP IgG 
(Sigma) that was diluted 1:1000 in TBS, pH = 7.2.  After 2 hours of incubation at room 
temperature, the antibody was aspirated and the wells were blocked with TBS + 5 g/L gelatin at 
room temperature for 45 minutes.  After the blocking solution was removed, diluted samples 
were added to the wells, with a series of samples of known concentration of hCRP to create a 
standard curve.  After 2 hours of incubation at 37 °C, the samples were removed and the wells 
were washed three times with ELISA buffer (TBS + 0.1% gelatin + 0.02% Tween-20).  A 100 
µL aliquot of the monoclonal mouse anti-CRP antibody HD2.4 (0.5 µg/mL) was then added to 
each well, followed by incubation for 1 hour at 37 °C.  After the wells were washed again three 
times with ELISA buffer, 100 µL of 1:1000 diluted HRP-labeled goat anti-mouse IgG (GE 
Healthcare) was added and left to incubate for 1 hour at 37 °C.  After a final round of three 
washes with ELISA buffer, the HRP substrate was added.  After a 10 minute incubation, the 
absorbance values were measured at λ = 405 nm. 
 
Protein Expression 
 Expression cultures were grown with methanol in 300 mL broth volumes in 1 L baffled 
flasks with orbital shaking at 30 °C; similarly, starter cultures were grown with glycerol in 50-
100 mL volumes in 250 mL baffled flasks.  The growth media BMGY and BMMY, described in 
the EasySelect™ Pichia Expression Kit, contain 1% yeast extract, 2% peptone, 100 mM 
potassium phosphate (pH = 6.0), 1.34% YNB, 4 x 10
-5
% biotin, and either 1% - 2% glycerol 
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(BMGY) or 0.5% - 1% methanol (BMMY).  Synthetic minimal media (SMM) contained 10 g/L 
monosodium glutamate, 2.5 g/L (NH4)2SO4, 100 mM KH2PO4 (pH = 5.0), 4 x 10
-5
% biotin, 
1.34% YNB, and either 2% glycerol or 0.5% - 1% methanol.  Multiple modifications of the 
SMM formula were attempted.   
In some media formulations, potassium phosphate was replaced with sodium 
hexametaphosphate (SHMP) to reduce precipitation; although, SHMP was found to be a poor pH 
buffer.  Some cultures received 0.1% - 0.5% glycerol or 0.5% - 1% sorbitol co-feeds with 
methanol during the induction phase; however, these co-feeds did not improve expression.  In 
many cultures, solutions of vitamins and minerals were prepared in the lab as a substitute for 
commercial YNB; however, these solutions were compositionally identical to YNB and did not 
improve culture growth or protein expression in comparison.  In addition to the pH values listed 
above, cultures were also grown under other conditions between 4.5 ≤ pH ≤ 7.0.  Some formulae 
were supplemented with 2% Casamino acids to limit extracellular proteolysis of the protein 
products.  Despite multiple attempts with a range of media formulations, the standard SMM 
medium was preferred due to composition control (relative to BMMG and BMGY) and formula 
simplicity (relative to other SMM formulations). 
 
Purification 
 All purification processes follow procedures previously described
31,38
.  Affinity 
chromatography with PCh-conjugated Sepharose (Pierce) used a loading buffer of borate 
buffered saline (BBS) (100 mM boric acid, 25 mM tetra-sodium borate, 225 mM NaCl, pH = 
8.35) with 3 mM CaCl2 and an elution buffer of BBS with 10 mM EDTA.  Eluted samples were 
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dialyzed overnight against Mono Q buffer A (20 mM Tris, 150 mM NaCl, 0.1 mM EDTA, pH = 
7.8).   
Anion exchange chromatography used a Mono Q column (5/50 GL Pharmacia #17-5166-
01) equilibrated with Mono Q buffer A and connected to a BioRad Biologic Duo Flow Protein 
Purification System.  After loading at 0.5 mL/min, proteins were eluted with a buffer gradient 
from 150 mM NaCl (Mono Q buffer A) to 1 M NaCl (Mono Q buffer B). 
HPLC gel filtration was performed using Superose 12 (10/300 GL Pharmacia #17-5173-
01) with a bed volume of 24 mL in a 10 x 300 mm column connected to a BioRad Biologic Duo 
Flow Protein Purification System.  The sample was prepared by concentrating 1.8 mL of Mono 
Q purified CRP to a final volume of 250 µL containing 480 µg of protein that was injected into 
the column.  Purified proteins were stored in TBS with 0.1 mM CaCl2. 
 
SDS-PAGE and Western Blotting 
 The 4%-20% SDS-PAGE gels were manually cast and run in Tris-Glycine buffer (25 
mM Tris, 192 mM glycine, 0.1% SDS, pH = 8.3).  These gels were run at 80 – 100 V until the 
samples entered the stacking gel and then at 180 V for 4 hours.  The 12% SDS-PAGE used a 
precast NuPAGE® Bis-Tris acrylamide gel (Life Technologies) in MOPS-SDS running buffer.  
Gels were stained with Coomassie blue stain. 
 Western blotting was performed by semi-dry transfer for 35 minutes at 25 V with PVDF 
in a Tris-glycine western transfer buffer (39 mM glycine, 48 mM Tris, 0.03% SDS, 20% 
methanol, pH = 8.9).  The membrane was blocked with 5% powdered milk in TBS overnight at 4 
°C.  The primary antibody was rabbit polyclonal anti-CRP and the secondary antibody was HRP-
conjugated donkey anti-rabbit IgG.  Results were visualized by ECL chemiluminescence. 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
Yeast Recombinant Expression Systems 
The yeast Pichia pastoris served as a suitable host for the transgenic expression of 
recombinant variants of the human proteins enteropeptidase, cathepsin G, neutrophil elastase, 
and C-reactive protein.  Although the results of protein expression in Kluyveromyces lactis were 
less successful, many of the issues at that time resulted from lack of user experience and limited 
availability of literature on the platform.  These recombinant protein expression studies yielded 
much experience regarding the fermentation of yeasts; however, the K. lactis constructs were 
abandoned in favor of the more familiar P. pastoris before much success was achieved.  The 
results of this work should not be taken to imply that the K. lactis system suffers from any 
inferiority as a recombinant expression system; contrarily, K. lactis shares many of the 
advantages of P. pastoris, as already discussed. 
 
Promoter Selection, Codon Optimization, and Custom Gene Synthesis 
 While the AOX1 methanol-inducible promoter provided strict control over protein 
production in P. pastoris, future work to express variants of these enzymes should use the 
constitutively active GAP promoter, based on recent research that indicates improved secretory 
capacity with GAP (Love et al. 2012).  Levels of recombinant protein expression for EP, CatG, 
HNE, and CRP never exceeded 5 mg/L; however, Life Technologies reports much higher 
production yields for P. pastoris.  The relatively low yields that were obtained may have been 
the result of poor secretion and not poor production.  The finding that red color accumulated 
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inside P. pastoris during the expression of CytB5-rhCatG and CytB5-rHNE suggests that much 
of the product was not secreted and may have led to intracellular protein degradation, as has been 
shown elsewhere to occur with use of the AOX1 promoter in P. pastoris (Love et al. 2012).  
Expression of these proteins under control of the GAP promoter may alleviate this problem. 
 It is impossible to say if codon optimization of the gene sequences had a significant 
impact on levels of protein expression without making a comparison to expression results for 
nonoptimized genes encoding the same protein.  Even then, confounding factors such as 
insertion cassette copy number, variations in secretory capacity, and other clone-to-clone 
variations have significant effects on protein expression levels that cannot always be predicted 
and can significantly affect the evaluation of codon optimization.  Indeed, screening of over 50 
transformant clones often yields only 1 or 2 with significantly higher expression levels for which 
the cause of improvement is unknown. 
Custom gene synthesis was found to have many advantages for simplifying the process of 
engineering recombinant proteins regardless of the usefulness of codon optimization.  This 
process made it easier to create the multisubunit CytB5 fusion constructs by eliminating the need 
for multiple PCR steps.  The disruption of numerous potential sites of glycosylation and kexin 
cleavage was also performed without the need for PCR-based site-directed mutagenesis and 
subcloning procedures. 
 
Glycosylation and Cleavage Site Disruptions 
 The disruption of glycosylation sites in rEP, rhCatG, and rHNE did not appear to 
adversely affect the enzymatic properties of any of these serine proteases; however, future 
studies may require serine proteases with native human glycosylation.  Recently, a new P. 
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pastoris expression system has been developed that allows users to select from several patterns 
of human glycosylation (Pichia GlycoSwitch®; http://www.rctech.com/licensing/gxt-pichia-
glycoswitch.php).  Use of this system not only eliminates the need to disrupt glycosylation sites 
but also allows recombinant production of proteins that more closely resemble their natural 
counterparts.  Future attempts to express recombinant human serine proteases in P. pastoris may 
benefit from a humanized glycosylation pattern. 
 The decision to disrupt potential sites of kexin proteolysis may or may not have improved 
protein expression.  Because previous attempts to express CatG from the human cDNA had met 
with only limited success, kexin proteolysis was proposed as a potential factor reducing 
expression.  It has been previously shown that high pI proteins like CatG do not express well in 
P. pastoris (Boettner et al. 2007) and the high frequency of dibasic sequences certainly indicates 
that kexin proteolysis may be a factor.  With some genetic manipulation, a strain of P. pastoris 
could be engineered by disruption of the KEX2 gene that would significantly reduce the 
vulnerability of dibasic sequences to proteolysis during secreted expression.  Although the 
expression products would retain the α-mating factor after secretion, the use of an EP cleavage 
site would enable removal of this N-terminal fusion domain without the need for kexin protease. 
 
Thoughts on Arginine Content and Recombinant Protein Expression 
 Although it is possible that a prevalence of dibasic sequences predisposes a yeast-
secreted recombinant protein to cleavage by kexin, at least 2 other possibilities may also be 
responsible for the poor expression of high pI proteins, as proved to be the case with rhCatG.  
First, proteins and peptides with high arginine content can have antimicrobial properties, as has 
previously been shown for CatG (Bangalore et al. 1990; Shafer et al. 1990; Shafer et al. 1991; 
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Miyasaki et al. 1993; Shafer et al. 1993; Shafer et al. 1996; Shafer et al. 2002).  While 
fermentation cultures of P. pastoris expressing CytB5-rhCatG did not display any signs of 
impaired growth rates or increased cell death, it is possible that highly basic proteins may 
interfere with intracellular function in other ways that could reduce production efficiency.  
Second, an excess demand for Arg could surpass the ability of the yeast to supply charged Arg-
tRNAs, resulting in a higher incidence of premature ribosome disassembly and accumulation of 
truncated protein products.  This potential problem could be exacerbated by an overabundance of 
one Arg codon in a codon-optimized sequence; however, careful regulation of protein production 
rates by limiting methanol availability and temperature could also counteract this issue by 
allowing the cells time to regenerate their supply of charged tRNAs.  As mentioned previously, 
absolute levels of tRNA abundance have not been characterized for P. pastoris and this 
information would greatly enhance the current work on codon optimization for the improvement 
of recombinant protein expression. 
 
Enteropeptidase:  Variations on a Theme 
 The recombinant expression of variants of hEPL proved very successful regarding the 
manipulation of this enzyme’s high level of substrate specificity.  While the reduced specificity 
of the R96Q substitution variant was of academic value for confirming the role of this residue in 
the extended substrate binding preferences of hEPL, the improved specificity conferred by the 
Y174R substitution has practical value for reducing nonspecific cleavages by this highly specific 
protease that is used in biotechnology to separate recombinant fusion protein domains.  Although 
it was not mentioned and no data was presented, studies with CatG indicated that the CatG 
substrate Suc-AAPF-SBzl was cleaved by EPL, likely due to the geometry of the EPL S1 
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specificity pocket, which appears to be large enough to accommodate the Phe residue of this 
synthetic substrate.  In an attempt to eliminate this undesirable activity, an EPL variant was 
attempted in which the residue Gly 226 was replaced with Asp, in addition to the Y174R 
substitution; however, this completely abolished the enzymatic activity of the protein, likely by 
limiting the size of the S1 specificity pocket. 
 Despite the failure of the G226D substitution to improve, or even retain, substrate 
specificity, further efforts to modify the extended binding site of EPL may yield further 
improvements on specificity or even facilitate the custom design, based on other similar serine 
proteases, of restriction proteases with novel substrate preferences.  The chymotrypsin-like 
serine protease granzyme B, for example, has a relatively strong preference for P1 Asp residues 
due to the presence of Arg 226 in the base of its S1 specificity pocket.  Because granzyme B and 
EPL both share the same chymotrypsin-like tertiary structure, residues with the same number 
share very similar positions regardless of the identity of the amino acid at the given position.  
Although the substitution G226R in EPL would likely limit the size of the S1 specificity pocket 
as was seen for G226D, the fundamental concept of altering the charge of this binding site could 
completely change the substrate specificity. 
 In one particularly promising design, either substitution D189R or D189K could 
completely convert the P1 preference of EPL from positively charged Lys or Arg to negatively 
charged Asp or Glu.  By itself, this change in substrate specificity would confer specificity for 
any poly-Asp sequence; however, the exact site of proteolytic cleavage might be difficult to 
control.  By adding the substitutions R96D and K99D, the substrate specificity of hEPL could 
theoretically be completely reversed from DDDDK~X to, for example, KKKKD~X.  Although 
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this may seem like an esoteric exercise, experimentation along these lines could result in novel 
approaches to engineer customized substrate specificity for biotechnological purposes. 
 
The Untold Story:  Other Expression Attempts with rhCatG and rHNE 
 The recombinant expression of rhCatG and rHNE was subject to many difficulties and 
multiple fusion partner domains were attempted prior to the successful results obtained with the 
CytB5 soluble heme-binding domain.  A table is provided that chronologically summarizes the 
attempted constructs (Table 5.1), all of which failed to yield the desired results. 
 
 
 
 The first attempted fusion was human serum albumin (HSA), which is the most abundant 
protein in blood plasma and displays a known affinity for the blue dye Cibacron Blue.  Although 
as much as 1.4 g/L of HSA has been expressed in P. pastoris (Kobayashi et al. 2000), this fusion 
partner did not provide a suitable “carrier protein” to facilitate production of rhCatG or rHNE.  
Because this was the first construct that was attempted, lack of positive results may have been 
caused by limited user experience; however, many other issues have been encountered since then 
that may have also contributed to the failure of the HSA fusion protein design.   
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In an effort to improve the detection of fusion protein production, enhanced green 
fluorescent protein (eGFP) was employed for its ease of detection, with an N-terminal 6xHis tag 
for purification.  All 6xHis tags employed in these designs were located at the N-terminus of the 
secreted protein and this leads to the purification of truncated protein products and partial 
degradation fragments.  Because the nature of this study required the production of enzymes with 
C-termini free of amino acid extensions, the more desirable C-terminal 6xHis tag could not be 
used.  Initial results with eGFP suggested that some protein was being produced by this method; 
however, very little activity and virtually no green fluorescence could be detected in the culture 
supernatant.  Later analysis of yeast cells using fluorescence microscopy suggested that this 
recombinant fusion protein may have been accumulating inside the cells, results that have since 
been reinforced by the intracellular accumulation of red color in P. pastoris cells expressing 
CytB5 fusion proteins. 
The third recombinant fusion domain, rubredoxin, was the first attempt by this lab to 
exploit a protein’s chromogenic properties for the detection of fusion constructs.  Rubredoxin 
binds iron atoms and displays an absorbance peak at λ = 410 nm; however, the extinction 
coefficient of rubredoxin at 410 nm is only 5.5% that of CytB5 (Mitra et al. 2005).  The 
recombinant expression of rubredoxin chimeras, much like eGFP, only resulted in low yields of 
enzymatic activity.  Curiously, the culture supernatant did display a rusty brown color; however, 
this color was a precipitate that settled upon centrifugation (15,000 – 21,000 x g). 
The presence of the rusty brown precipitate was tantalizing because it had not been 
observed with the previous fusion constructs.  At this time, other chromogenic proteins were 
evaluated as candidates and CytB5 was selected based on previous success with this fusion 
domain in E. coli (Finn et al. 2005; Mitra et al. 2005).  While this later proved to be the most 
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successful attempt at expressing rhCatG and rHNE in P. pastoris, the CytB5 fusion construct 
was at one time discarded due to difficulties with the 6xHis-IMAC purification process.  Initial 
results showed acceptable levels of protein expression for both enzymes; however, the proteins 
did not adsorb well to IMAC resin charged with Ni
2+
, Co
2+
, or Cu
2+
. 
After many attempts to improve IMAC purification yields for CytB5 fusion proteins, a 
new approach was devised using the small ubiquitin-like modifier (SUMO) protein as a fusion 
tag.  Due to continued success with recombinant expression of EPL, 2 versions of the SUMO 
fusion were constructed apiece for rhCatG and rHNE, one with the EPL cleavage linker sequence 
DDDDK and another lacking this sequence, being activated instead by a protease specific to 
SUMO.  Neither of these constructs yielded significantly better production results than the 
CytB5 fusion proteins.  Activation with the SUMO protease was costly because, unlike EPL, 
SUMO protease was not available from recombinant expression system in the lab. 
 
Improving the Purification of CytB5-rhCatG and CytB5-rHNE 
Fortunately, further research proved that the issues with 6xHis-IMAC purification of the 
CytB5 were surmountable.  Of particular note, many manufacturers’ protocols indicate that Tris 
can be used as a suitable buffer, but that it can also impair 6xHis binding to IMAC resin.  For the 
purification of CytB5-rhCatG and CytB5-rHNE, Tris was found to interfere with this stage of the 
purification process.  In contrast, phosphate buffers were found to significantly improve protein 
binding to IMAC.  Also, as-yet unidentified components of spent P. pastoris fermentation media 
seem to interfere with 6xHis-IMAC purification.  While buffer exchange by membrane 
ultrafiltration improved IMAC purification yields, these proteins were eluted under very low 
concentrations of imidazole (20 – 50 mM) and were difficult to separate from other contaminants 
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that dissociated from the column under the same imidazole concentrations.  Future attempts to 
improve the expression of rhCatG and rHNE by these methods should employ a deca-histidine 
(10xHis) tag (or longer) for improved Ni
2+
 affinity because this may increase the concentration 
of imidazole required to elute the protein of interest and could improve efforts to eliminate 
contaminants.  
The more significant difficulty that was encountered in the purification of rhCatG and 
rHNE was the failure to recover these activated enzymes by affinity chromatography for basic 
pancreatic trypsin inhibitor (BPTI, Trasylol®).  Attempts to use secretory leukocyte proteinase 
inhibitor (SLPI) in place of BPTI succeeded in adsorbing over 99% of active rHNE and native 
HNE; however, the extremely tight binding interactions between HNE and SLPI proved very 
difficult to break.  Because BPTI has been used routinely in the purification of HNE and CatG in 
the past (Baugh and Travis 1976), the efficiency of the BPTI column that was used is called into 
question. 
The BPTI columns used in these experiments were created by coupling BPTI to N-
hydroxysuccinimide (NHS) reactive groups on the surface of an agarose support matrix (BioRad 
Affi-Gel® 10).  These NHS groups react with the side chain amino groups of Lys residues.  
BPTI only contains 4 Lys residues; furthermore, 1 of these, Lys 15, is the P1 residue of the 
active site of this reversible protease inhibitor.  By coupling BPTI to NHS-agarose without first 
blocking the active site residue Lys 15, a significant portion of the total BPTI bound to the resin 
will be inactivated by the reaction of Lys 15 with NHS.  To ensure that 100% of the BPTI 
coupled to the column is active, the BPTI should first be equilibrated with excess acetylated 
trypsin (Ac-trypsin) to block Lys 15.  Ac-trypsin has no free amines available to react with NHS-
agarose; consequently, it will not couple to the resin.  Because the BPTI-trypsin interaction is 
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pH-dependent, BPTI can be coupled to NHS-agarose using the other Lys residues while Lys 15 
is blocked with Ac-trypsin.  This protease can then be eluted from the column by lowering the 
pH.   
It is proposed that the BPTI columns used during this work did not contain a high enough 
concentration of functionally active BPTI to efficiently adsorb the low concentrations of rhCatG 
and rHNE present in samples.  BPTI affinity matrix prepared using Ac-trypsin, in the manner 
described above, could circumvent this problem and drastically improve the purification of these 
enzymes by the well-established method of BPTI affinity chromatography. 
 
Learning to Fly:  Lessons in Recombinant Yeast Fermentation 
 The single largest hurdle in the successful expression of large amounts of recombinant 
proteins by yeast is the control and optimization of growth conditions.  Bioreactor-based 
fermentation methods are strongly recommended over methods that use baffled flasks because of 
the increased level of control that bioreactors afford.  Careful regulation of carbon, nitrogen, 
oxygen, phosphate, pH, and temperature significantly improve efforts to optimize culture growth 
conditions.  When working with the methanol-inducible AOX1 promoter, it is very important to 
properly regulate the concentration of methanol in solution to prevent its accumulation to toxic 
levels.  High-yield protein production also requires adequate supplies of oxygen that cannot 
always be supplied by normal air.  The pH of a yeast culture does not remain static throughout its 
growth and cannot be held constant in baffled flasks.  Bioreactors enable the careful regulation 
and incremental modification of culture growth conditions and facilitate optimization of growth 
media.  Bioreactor-based fermentation of yeast, especially P. pastoris, is detailed in the 
appendix. 
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APPENDIX 
ON BIOREACTOR BASED FERMENTATION OF YEAST 
 
 Recombinant yeast can be grown to high density in large volumes through the use of 
bioreactor fermentation; furthermore, bioreactors facilitate monitoring and regulation of culture 
conditions to provide an optimal growth environment for maximized protein production.  Factors 
such as temperature, acidity, and the bioavailability of several compounds can be controlled with 
more accuracy and consistency in bioreactors than in the baffled flasks routinely used for culture 
screening.  Despite the additional factors to which the operator must attend, bioreactor 
fermentation occurs on a time scale similar to that of the baffled flask platform, does not require 
much additional effort, and results in higher yield of recombinant protein.  Numerous review and 
methods papers have been published (Stratton et al. 1998; Cereghino and Cregg 2000; Cereghino 
et al. 2002; Zhang et al. 2002; Zhang et al. 2003; Plantz et al. 2006; Li et al. 2007; Bollok et al. 
2009; Murasugi 2010; Ramón and Marín 2011; Bawa and Darby 2012; Bora 2012; Damasceno 
et al. 2012).   
 
Considerations for Media Formulation  
 Although complex media based on yeast extract and peptone are frequently used for 
recombinant protein production in yeast, synthetic media provide many advantages, regardless of 
the scale on which production will occur.  Because they are derived from biological sources, 
yeast extract and peptone are complex mixtures of poorly defined components; however, 
synthetic media assembled from pure compounds provide a well-defined environment of 
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specified composition and often result in improved culture growth rates and recombinant protein 
production. 
 For the bioreactor fermentation of P. pastoris, the formulation prescribed by the Pichia 
Fermentation Process Guidelines (Life Technologies), designated Basal Salts Medium (BSM) 
and supplemented with PTM1 Trace Salts, is used most frequently and is based on the formulae 
used during the early development of this recombinant expression platform (Siegel and Brierley 
1989; Brierley et al. 1990), although variations on this recipe such as FM22 (Stratton et al. 1998; 
Wang et al. 2005) with PTM4 (Stratton et al. 1998) are often used (Table A1).  All synthetic 
media must include bioavailable sources of carbon, oxygen, nitrogen, and phosphate in addition 
to several other ions including especially calcium, magnesium, potassium, and sulfate (Siegel 
and Brierley 1989).  The sources of these components, their concentrations, and the method of 
their assembly can have significant impact on fermentation results and must be considered in 
detail. 
 
Table A1:  Fermentation Media Components 
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Carbon Sources 
 The carbon sources made available to yeast during fermentation may or may not impact 
the rate of protein production depending on the chosen transcriptional promoter.  For P. pastoris, 
the two promoters most frequently used to direct recombinant expression are the alcohol oxidase 
1 (AOX1) promoter and the glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter.  The 
GAP promoter is constitutively active and not sensitive to environmental conditions; however, 
the AOX1 promoter is repressed by several carbon sources and induced only in the presence of 
methanol.  The GAP promoter is useful for expression of foreign proteins that do not adversely 
affect culture growth because it does not require any special induction strategy.  Such cultures 
can be grown to high density in glucose or glycerol and they express the gene product throughout 
the fermentation.  Protein expression based on the K. lactis platform often uses the galactose-
inducible β-galactosidase gene promoter LAC4, which, like AOX1, is repressed by other carbon 
sources. 
 Use of an inducible promoter provides tight control over recombinant protein expression, 
which can be useful for the production of toxic proteins; however, this strategy requires careful 
control of carbon compounds that are available.  The AOX1 promoter is only induced by 
methanol and is repressed to varying degrees by many sugars and alcohols including glucose, 
ethanol (by conversion to acetate), and glycerol.  Typically, fermentation of yeast using an 
inducible promoter begins with rapid culture expansion using glycerol as the carbon source 
followed by induction in the absence of glycerol.  Supplementation of culture media with 
monosodium glutamate (MSG) can improve culture growth without repressing recombinant 
protein expression.  Reducing sugars such as glucose and galactose must be autoclaved 
separately from BSM containing primary amines to prevent Amadori or Maillard reactions; 
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however, non- reducing carbon sources like the sugar alcohols glycerol and sorbitol do not react 
with primary amines and can be included in the BSM prior to autoclave sterilization.  Sorbitol 
has been shown to improve protein expression when used as a cofeed with methanol during the 
induction phase of growth (Holmes et al. 2009; Wang et al. 2010). 
 
Oxygen Sources 
Although comparative investigations of the effects of various gas mixtures on 
recombinant expression have not been reported and the effects of excess O2 are unclear, the 
availability of dissolved O2 gas is fundamental to yeast culture growth.  Because all of the 
potential pre-induction carbon sources are catabolized through the central glycolytic pathway, 
the yeast cells require sufficient oxygen for aerobic respiration at all times to prevent the 
accumulation of anaerobic ethanol and acetate that will inhibit recombinant expression driven by 
the AOX1 promoter (Inan and Meagher 2001).  For Mut
s
 (including strain KM71H) or Mut
+
 
(including strains X-33, GS115 or SMD1168H) P. pastoris as well as all strains of K. lactis, the 
same rationale applies to the induction phase.     
In the case of Mut
+
 P. pastoris fermentation, the cells metabolize methanol like the wild-
type and consume large amounts of methanol during the induction phase; furthermore, methanol 
catabolism requires oxygen during two phases (Veenhuis et al. 1983; Cereghino and Cregg 
2000).  First, the conversion of methanol to formaldehyde by alcohol oxidase is directly 
dependent on oxygen and methanol will accumulate to lethal levels in the prolonged absence of 
sufficient oxygen.  Second, the subsequent conversion of formaldehyde to CO2 is a 2-step 
oxidation accompanied by the total reduction of 2 NAD
+
 to 2 NADH that then drive aerobic 
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respiration.  In the event of oxygen depletion, NADH cannot be oxidized to replenish the NAD
+
 
pool sufficiently to prevent the toxic accumulation of intracellular formaldehyde. 
 
 
Figure A1:  Catabolism of Methanol.  The catabolism of methanol is a three step process that 
requires oxygen, both directly in the oxidation of methanol to formaldehyde and indirectly in the 
oxidation of NADH by the electron transport chain (e- Transfer) to replenish intracellular NAD
+
.  
Mut
s
 strains, such as KM71H, grow slowly on methanol because the AOX1 gene has been 
disrupted and the cells must use the weaker AOX2 gene for methanol metabolism. 
 
Nitrogen Sources 
 Bioavailable nitrogen is provided as ammonium (NH4
+
), either in the form of ammonium 
hydroxide or ammonium sulfate.  The choice of nitrogen source for the growth media depends on 
the acidity of the initial solution.  For media formulated with phosphoric acid, such as BSM, the 
amount of ammonium hydroxide required to increase the pH supplies sufficient initial nitrogen 
content for the yeast.  Other media may use less acidic phosphate sources like potassium 
phosphate or sodium hexametaphosphate (SHMP) that do not require neutralization by 
ammonium hydroxide.  In these cases, the media must be supplemented with ammonium sulfate 
as it provides a nitrogen source without affecting the pH.  Regardless of the initial formulation, 
metabolically active P. pastoris continuously acidify the culture media and consume nitrogen 
during fermentation; consequently, the bioreactor monitors the culture pH and can be set to 
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automatically add ammonium hydroxide to maintain the desired pH while feeding the cells 
nitrogen.   
 
Phosphate Sources 
 The BSM recipe includes phosphoric acid as the source of bioavailable phosphate 
whereas the FM22 medium uses monobasic potassium phosphate.  While these compounds 
affect the pH differently and determine which nitrogen source to include, they both contain 
inorganic orthophosphate, PO4
3-
.  The PO4
3-
 ion is required by all organisms and must be 
abundant for successful fermentation; furthermore, orthophosphate provides a pH buffer for the 
growth media.  Unfortunately, many salts of orthophosphate exhibit poor solubility, including 
calcium, iron, and zinc salts.  Fermentation media made with orthophosphate typically contain 
some insoluble phosphate salts and the amount depends on the temperature and pH of the 
solution as well as the calcium, iron, zinc, and phosphate concentrations.  Because the PTM1 
trace salts solution contains more ferrous sulfate and zinc chloride than PTM4, fermentation 
media containing PTM1 typically develop more insoluble precipitate than those containing 
PTM4. 
 Sodium hexametaphosphate (SHMP, or “phosphate glass”), (NaPO3)6, can be substituted 
for orthophosphate to prevent the formation of insoluble salts; however, SHMP does not buffer 
pH effectively and decomposes into orthophosphate at elevated temperature.  In media 
formulations that use SHMP instead of orthophosphate, a suitable pH buffer such as MES is 
suggested in order to facilitate bioreactor regulation of pH; however, acetate must be avoided as 
a pH buffer because it represses the AOX1 promoter (Inan and Meagher 2001).  SHMP must be 
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sterilized separately by ultrafiltration and added aseptically after the sterile fermentation vessel 
has cooled to prevent SHMP decomposition into orthophosphate. 
 
Trace Elements and Other Supplements 
 The final fermentation media require a number of trace elements that are combined into a 
filter-sterilized, concentrated supplement and added to cool, sterile BSM in the fermentation 
vessel.  The two most commonly used trace element supplements are PTM1 and PTM4 and these 
formulations vary primarily in the relative concentrations of several components.  PTM1 was 
found to produce more insoluble precipitate at neutral to alkaline pH than PTM4, despite 
additional calcium, likely because of the additional masses of ferrous sulfate and zinc chloride in 
PTM1 that form insoluble orthophosphate salts in the media.  It has been shown that increased 
levels of biotin supplementation improve recombinant protein expression in P. pastoris (Jungo et 
al. 2007).   
While both PTM1 and PTM4 supplements contain biotin, it is suggested here that 
additional biotin be provided.  Similarly, fermentations of P. pastoris or K. lactis may or may not 
benefit from a supplementary vitamins mix, made as a 100x concentrate containing 0.1 g/L L-
His-HCl, 0.2 g/L DL-Met, 0.2 g/L DL-Trp, 0.0002 g/L biotin, 0.0002 g/L folic acid, 0.2 g/L 
inositol, 0.04 g/L niacin, 0.02 g/L p-aminobenzoic acid, 0.04 g/L pyridoxine HCl, 0.02 g/L 
riboflavin, 0.04 g/L thiamine HCl, 0.04 g/L calcium pantothenate, 10 g/L CaCl2.  These optional 
supplements do not impair but may improve culture growth and protein expression; furthermore, 
they are components of the Yeast Nitrogen Base (YNB) generally used in many yeast media. 
Bioavailability of free amino acids in the fermentation media may improve secreted 
recombinant protein expression by reducing the demand for amino acid biosynthesis and 
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alleviating the drain placed on the cellular amino acid pool by the overexpression of recombinant 
proteins.  Proteins directed for secretion into the growth media may be susceptible to inactivation 
or degradation through the actions of secreted neutral proteases and amino acid supplementation 
of the media may reduce the expression of these yeast proteases.  Casamino acids are one option, 
but they are a complex mixture of amino acids and peptide fragments from the acid hydrolysis of 
casein.  As an alternative, a mixture of pure amino acids can be assembled with a known, 
controlled composition. 
 
Fermentation Medium and Bioreactor Setup and Assembly 
 Prior to culture growth, the sterilization and assembly of the fermentation medium and 
the bioreactor vessel must occur.  This process consists of 3 sequential phases of assembly, based 
on sterility and temperature, where each phase includes a prescribed set of steps required for 
correct fermentation conditions and bioreactor operations.  The procedures described here 
demonstrate the use of the BioFlo® 110 Bioreactor (New Brunswick) but also apply to other 
similar apparatus.   
 
Setup Phase 1:  Presterile Assembly 
 Initial Medium Preparation.  To begin, the initial components of the fermentation 
medium are solubilized into deionized water and added into the fermentation vessel.  The initial 
volume for a 7.5 L vessel should be approximately 2.5-3.0 L of medium containing enough of 
each ingredient per liter for 3.5 L of total medium.   
The synthetic fermentation media formulations tried during the production of 
recombinant enzymes described in Chapters 2, 3, and 4 are variations based on the BSM recipe 
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recommended by Life Technologies and the FM22 recipe created by Stratton et al. (Stratton et al. 
1998).  The formulae of these media are provided in Table A1, above.  Some formulations are 
supplemented with 10 g/L monosodium glutamate (MSG) (Boettner et al. 2002).   
Provided that the phosphate source is an orthophosphate like phosphoric acid or 
potassium phosphate, it can be included at this time.  SHMP must be filter sterilized and added 
during setup phase 3 because it decomposes into orthophosphate at elevated temperatures.  A 
nonreducing carbon source like glycerol can also be included here; however, reducing sugars 
such as glucose and galactose must be autoclaved separately and added during setup phase 3. 
If the phosphate source is phosphoric acid, then no nitrogen source is required in the initial 
solution; however, 5 – 10 g/L ammonium sulfate should be included if the phosphate source is a 
potassium salt. 
 Bioreactor Setup and Sterilization.  The fermentation vessel containing the initial medium 
preparation is assembled with the head plate and rubber seal seated securely.  During heat 
sterilization, all head plate openings into the container must be sealed with the exception of the 
exhaust tube, which should be stoppered with a gauze plug.  For the external opening of the 
metal oxygen sparging pipe, polymer tubing such as Tygon® should be attached, with a slip knot 
tied tightly in the free end; otherwise, pressure from the heated gas in the vessel will push liquid 
out through this opening.  All other metal ports that open into the interior of the vessel should be 
similarly sealed with knotted tubing.  An image of the head plate, prepared for autoclave 
sterilization, is shown (Figure A2). 
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Figure A2:  Bioreactor Vessel Head Plate.  The bioreactor head plate is shown, from above, 
immediately prior to autoclave sterilization.  All important components of the head plate are 
labeled.  All ports that expose the vessel interior are “capped” or “plugged” and all ports that do 
not expose the vessel interior are “open.” 
 
 The bioreactor makes use of a dissolved oxygen (dO2) sensor to monitor the percentage 
of dissolved oxygen in the media, relative to a calibrated range of dO2 content.  This metal probe 
must be handled very carefully to avoid damaging the exposed membrane at its tip; however, it 
can be mounted in the head plate prior to the subsequent sterilization of the vessel.  The 
calibration of this probe occurs during setup phase 3.  The probe contains an electrolyte solution 
that may require infrequent replenishment and a bottle of this is provided by the manufacturer. 
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 The pH probe can be mounted in the head plate prior to autoclave treatment; however, 
this probe must be calibrated using standardized pH buffers prior to sterilization.  As an 
alternative, the pH probe can be sterilized with ACS methanol immediately prior to insertion into 
a sterile vessel.  The calibration of this probe requires standardization to two set points, “zero” at 
pH = 7.0 and “span” at pH = 4.0. 
 Autoclave sterilization proceeds on a liquid cycle lasting 30 minutes at 121 °C. 
 
Setup Phase 2:  High Temperature Sterile Assembly 
 Once the fermentation vessel and medium have been heat sterilized, the vessel’s closed-
circuit coolant piping is connected to an external liquid cooling unit containing antifreeze.  This 
cooling unit is turned on and set to 25 °C; furthermore, care must be taken to ensure that the 
coolant reservoir is full and that all air is bled from the coolant lines because this can impede 
proper temperature regulation.  A temperature sensor connected to the bioreactor control module 
(“the tower”) is inserted into a metal pipe that extends into but does not open on the interior of 
the vessel.  Until the vessel and medium have completely cooled, the oxygen sparger tubing 
should remain tied and the exhaust tube should remain plugged with gauze.  The electrical 
impeller motor can be mounted on the impeller driveshaft and connected to the tower, ensuring 
that the rubber seal of the driveshaft is always well-lubricated with vacuum grease.  The impeller 
can be set at low speed (≤ 350 rpm) to reduce vessel cooling time or the vessel can be allowed to 
cool overnight.  If the pH probe was not calibrated and inserted prior to vessel sterilization, this 
should be done now.  The dO2 probe must be connected to the tower and allowed to polarize for 
a minimum of six hours prior to calibration in setup phase 3.   
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Setup Phase 3:  Final Assembly 
 After the vessel has cooled to between 25 °C and 30 °C, the oxygen sparger tubing can be 
connected to the oxygen supply tank via a regulator, an airflow meter, and a 0.22 µm in-line 
filter.  The exhaust tube can be connected to the liquid cooled exhaust condenser that is attached 
to tubing that bubbles exhaust gas through dilute chlorine bleach in an Erlenmeyer flask.  The 
sampling apparatus is mounted on the head plate and connected by tubing to the metal sampling 
pipe.  The impeller should be set at 350 rpm.  Images of the connected bioreactor vessel (Figure 
A3) and bioreactor control tower (Figure A4) are shown. 
 
 
Figure A3.  Bioreactor Vessel.  The bioreactor vessel is shown that illustrates the connection of 
the assembled fermenter.  The impeller motor has been mounted on the impeller driveshaft.  The 
impeller motor, pH probe, dO2 probe, and temperature sensor are connected to the bioreactor 
control tower (see Figure A4).  The air inlet hose, the exhaust hose, and the main coolant lines 
are obscured in this image.  Refer to Figure A2 for locations of these ports.  
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Figure A4.  Bioreactor Control Tower.  The bioreactor control tower is shown with all 
connections to the bioreactor vessel (left).  The pump head contains four peristaltic pumps 
regulated by the control tower.  These pumps can be programmed to feed acid, base, antifoam, or 
other agents either at constant rates or in response to pH and foam sensors.  A separate pump is 
used for delivering the carbon feed for improved volumetric regulation of the feed rate.  The 
bioreactor control tower is modular and can be arranged in other ways.  The digital interface unit 
(computer) for the control tower is stacked above the dO2/pH probe inputs and cannot be seen in 
this image (see Figure A5). 
 
Final Medium Assembly and pH adjustment.  The remaining components of the 
fermentation medium are added aseptically at this time into the stirring fermentation vessel.  The 
trace elements solution (e.g. PTM1 or PTM4) is added to the appropriate final dilution.  Extra 
sterile components such as biotin, a vitamins mix, amino acid supplements, SHMP, and reducing 
sugars can also be added at this time.  Once these components have been added, the bioreactor is 
setup for pH control. 
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Figure A5.  Bioreactor Digital Interface.  The digital interface of the control tower is shown.  
This computer monitors and displays sensor data in real-time.  The context-specific buttons make 
selections as indicated adjacently on the digital screen. 
 
 The tower can be programmed through the digital interface to activate acid and/or base 
feed pumps in response to deviations of culture pH from the set point.  An image of the digital 
interface (Figure A5) is shown for reference, see the bioreactor user’s manual for details.  In the 
case of P. pastoris, the growing culture acidifies the media; consequently, the base pump is setup 
to provide a regulated drip feed from a reservoir of ACS ammonium hydroxide diluted 1:1 into 
deionized water.  The tubing from the base pump is connected to the head plate of the 
fermentation vessel.  Only then is the tower set to regulate the pH and the pump turned on.  If the 
pH of the broth is below the desired set point, then the bioreactor will add ammonium hydroxide 
at this time to adjust the pH.  Culture pH affects the activity of extracellular proteases that can 
degrade recombinant protein secreted into the medium.  The unwanted activity of neutral 
proteases can be prevented by the addition of broad spectrum protease inhibitors or reduction of 
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the culture pH when inhibitors are undesirable; consequently, P. pastoris fermentations are 
frequently conducted at pH < 5.0, especially during induction. 
 dO2 Probe Calibration.  To ensure proper monitoring of the dissolved oxygen content of 
the culture, the dO2 probe must be calibrated.  First, the “zero” set point is established.  This can 
be accomplished by disconnecting the probe from the tower just long enough for the raw reading 
to stabilize (about 2 seconds) or by sparging the medium with pure nitrogen gas until the raw 
reading stabilizes.  After the minimum raw reading has been reached, the “zero” set point is set 
to 0 %. Second, the “span” set point must be established.  For this, the oxygen flow rate is set to 
1 vvm (volume of gas per volume of culture per minute), e.g. 3.5 LPM (liters per minute) of 
oxygen for a 3.5 L liquid volume, and the impeller motor is set to its highest speed (1200 rpm for 
a New Brunswick BioFlo-10 bioreactor).  The fermenter must then be left undisturbed until the 
raw reading reaches a stable maximum, approached asymptotically, at which point the “span” set 
point is entered as 100.0 %, representing the maximum amount of oxygen driven into solution at 
equilibrium by the given gas supply under maximum stirring conditions.  Physical chemistry 
dictates that the equilibrium of dissolved O2 at constant temperature and pressure is directly 
proportional to both the partial pressure of O2 in the gas and the surface area of the gas/liquid 
interface; consequently, pure oxygen and maximum stir rates maximize the absolute amount of 
O2 dissolved at equilibrium.  Once the probe is calibrated, the O2 supply can be turned off until 
the culture is inoculated.    
 Throughout the fermentation of yeast, assessments of culture health and metabolism rely 
on the careful observation and accurate interpretation of changes in dO2 content and impeller 
behavior because the respiration reflects carbon consumption, both critical components for high 
yield culture expansion and protein production. 
183 
 
Yeast Fermentation 
 Bioreactor based fermentation of yeast using a repressible/derepressible transcriptional 
promoter like AOX1 and LAC4 consists of four culture growth stages: inoculum growth, pre-
induction batch phase, pre-induction fed-batch phase, and induction fed-batch phase.  The 
culture inoculum expands while consuming the available carbon during the preinduction batch 
phase.  Upon carbon depletion, the pre-induction fed-batch phase further increases the culture 
density with the drip-fed addition of concentrated pre-induction carbon source at a regulated rate.  
A culture of sufficient density is then transitioned to a drip-feed of the carbon source required for 
the induction fed-batch phase.  Yeast transformants using a constitutive promoter only require a 
batch phase followed by a fed-batch phase, with no distinction based on induction; however, the 
general procedures remain the same. 
 
Inoculum Growth 
 Two days prior to fermenter inoculation, a 10 mL liquid seed culture of the yeast is set to 
grow with shaking at 30 °C overnight in YPD with antibiotics (100 µg/mL Ampicillin and, for P. 
pastoris, 100 µg/mL Zeocin) to which the strain is resistant. On the day before fermenter 
inoculation, the starter culture in a nutrient-rich synthetic minimal medium (SMM) is seeded 
from the YPD culture.  This starter culture is grown for 24 – 36 hours with shaking at 30 °C in a 
1 L baffled shaker flask that is filled approximately 1/3 with SMM containing the pre-induction 
carbon source, often glycerol.  The starter culture should be grown to high density and the 
volume of inoculum should not exceed approximately 10 % of the initial fermentation volume. 
 Inoculation of the fermentation vessel proceeds only after the completion of bioreactor 
setup and assembly.  The entire starter culture volume is added aseptically to the fermentation 
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vessel and a 25 ml sample is immediately withdrawn and centrifuged to determine the wet cell 
pellet weight (WCW) in grams per liter of medium.  Throughout the fermentation process, such 
25 ml samples will be collected at least once per day and at the start of every phase of 
fermentation; furthermore, the WCW data should be graphed over time to monitor the health and 
growth rate of the culture, which should continue to expand throughout the fermentation. 
 
Preinduction Batch Phase 
 Once the fermentation vessel has been inoculated, the culture enters the pre-induction 
batch phase, during which it consumes the supply of bioavailable carbon in the broth.  At the 
time of inoculation, the bioreactor control tower should be set up to automatically regulate the 
dO2 by adjusting the impeller speed.  The dO2 set point should be no less than 35 % to ensure 
that the actual dO2 of the culture does not drop below 20 %; furthermore, the impeller speed 
range should be set between a minimum of 350 rpm and the maximum allowable speed (1200 
rpm for a New Brunswick BioFlo-10 bioreactor) for automatic speed control.   
The starting dO2 will likely be above 95 % due to saturation from probe calibration.  As 
the culture grows, the dO2 will gradually fall until it drops below the dO2 set point, at which 
time the impeller speed will be automatically increased to compensate for the increased oxygen 
demand.  Changes in the dO2 content of the medium reflect the metabolic health of the culture 
and the bioavailability of carbon; consequently, careful dO2 monitoring throughout all stages is 
critical to successful fermentation. 
The preinduction batch phase lasts until the culture has depleted the bioavailable carbon 
in the growth medium.  The end of this phase is marked by a reduced oxygen demand of the 
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yeast in response to the lack of carbon and a significant increase of the dO2 above the 
programmed set point, despite a reduction in impeller speed to its minimum.   
 
Preinduction Fed-Batch Phase 
At this time, a steady pump-fed, drop wise addition of the pre-induction carbon source is 
initiated.  A sterile solution of 50 % glycerol in deionized water is recommended with a feed rate 
of 1 mL/min (Bio-Rad Econo peristaltic pump) for a 3.5 L culture volume (17 – 18 mL/hr per 
liter of initial volume).  The culture will respond to the addition of fresh bioavailable carbon by 
increasing the oxygen demand, as evinced by a steady reduction of dO2 and an increased 
impeller speed.  This phase lasts until the culture density has reached a wet cell pellet weight 
(WCW) of 180 – 200 g/L, approximately 4 – 6 hours.   
By the end of the preinduction fed-batch phase and throughout the rest of the 
fermentation, the culture should also be carbon limited, with a carbon consumption rate equal to 
the carbon addition rate so that no excess feed accumulates in the medium.  A carbon limited 
culture runs out of carbon source very shortly after the drip feed is turned off and this results in a 
rapid increase in dO2 (a dO2 spike), usually within two minutes.  Carbon limitation at the end of 
the pre-induction fed-batch phase ensures that no promoter repressing carbon compounds 
interfere with the induction phase. 
 
Induction Fed-Batch Phase 
 A carbon limited yeast culture of WCW = 180 – 220 g/L is ready for induction, which is 
initiated simply by changing the carbon feed.  In the case of P. pastoris controlled by AOX1, the 
transition to methanol must occur in stages to allow the yeast time to adapt.  The initial feed rate 
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of pure methanol, 3.6 mL/hr per liter of initial fermentation volume, is maintained for 3 – 4 
hours, until the dO2 holds steady and dO2 spikes occur quickly.  At this time, the methanol feed 
rate is doubled to 7.2 mL/hr per liter of initial volume and maintained for 2-3 hours, after which 
the culture is tested again for carbon limitation by the dO2 spike method.  If a dO2 spike occurs 
shortly after terminating the methanol feed, then the culture is carbon limited and the feed rate is 
increased to 10.9 mL/hr per liter, where it remains until the end of fermentation.  The induction 
fed-batch phase usually lasts for about 72 hours, with an average feed rate of 10.4 mL/hr per 
liter.  These feed rates follow the recommendations of the Life Technologies Pichia 
Fermentation Process Guidelines.  Not all transformants will produce proteins optimally under 
these conditions; consequently, the feed rates and fermentation time may require adjustment to 
maximize protein production. 
 It has been shown that supplementation of the methanol feed with sorbitol improves 
culture growth and protein yields (Holmes et al. 2009; Wang et al. 2010).  Because it does not 
dissolve in pure methanol, sorbitol should be fed through a separate line rather than dissolved 
into methanol diluted with water.  Diluted methanol requires a faster feed rate than pure 
methanol to provide the same amount of carbon, which dilutes the culture and reduces the 
growth rate; furthermore, the volume of water added to the fermentation during fed-batch phases 
should be minimized to prevent the culture volume from exceeding the capacity of the vessel. 
 Carbon limitation should be evaluated periodically throughout the induction fed-batch 
phase to ensure that methanol does not accumulate in the vessel over time, as excess methanol is 
toxic.  To verify that the culture is carbon limited, the drip feed is stopped and the time to the 
dO2 spike is observed by monitoring both the dO2 reading and changes in the impeller speed.  It 
is important to confirm that an increase in dO2 is actually a spike and not just in response to an 
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increase in the impeller speed.  For a true spike, the dO2 will continue to rise even as the impeller 
speed falls. 
 
Culture Harvest 
 After completion of the induction fed-batch phase, the culture is harvested from the 
fermentation vessel.  Although several approaches are available for recovering the culture 
volume, the use of oxygen pressure is suggested to drive the broth out through the sample 
collection tube.  This can be achieved by clamping the exhaust tubing, unclamping the sample 
collection tubing, and collecting the stream of liquid directly into centrifuge bottles, which 
minimizes the amount of clean up that is required.  The yeast should be centrifuged with a 
relative centrifugal force of 5,000 – 10,000 x g for 10 – 20 minutes or until all cells have formed 
a pellet.  For proteins that are retained by the yeast, the cells can be lysed by a variety of methods 
including mechanical disruption (e.g. glass beads), enzymatic treatment (e.g. lyticase), repeated 
freeze/thaw cycles, sonication, or the use of a French pressure cell.  For proteins secreted by the 
yeast, the culture supernatant is further clarified after separation from the cell pellet.  The 
supernatant can be passed through glass fiber prefilters as well as submicron filter membranes 
made of low protein binding materials like polyethersulfone (PES). 
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